The Royal College of Pathologists
Pathology. the science behind the cure
Annual report and financial statements
For the year ended 30 June 2022
Reglstered charlty number 261035
The Royal Co11898 ol PathollSts
6 Alie St[ London, E1 8aT, UK
Td.. 020 74516700, ww.rcpath.org
¢)
The Royal College of Pathologists
Index to the financial statements
Pa
Report of the trustees
Report of the auditors
12- 14
Consolidated statement of financial activities
15
Consolidated and College balance sheets
Consolidated statement of cash flows
17
Accounting policies
18-20
Notes to the financial statements
20-32
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
The Tnjstee Board are pleased to present their report together wtth thè fir)ancial statements of the
College for the year ended 30 June 2022.
Objectives & activities
The College's mission is to promote excellence in the practice of pathology and maintain standards
through training, assessments, examinations and professional development, to the benefit of the
public. The trustees have complied with the duty in the Charities Act 2011 to have due regard to
guidance published by the Charity Commission, including public benefft guKJance.
Pathology is the science at the heart of modem medicine, vital for the understanding, diagnosis and
planning clinical management of disease. 95 % of patients will have a pathologist involved in their
healthcare journey. (https.//wMv.england nhs.uklwp4ontentlupR08cl&Q014J02/p&thol*ig-fjrstpdg
Pathologists study the causes of disease and the ways in which disease processes affect our bodies.
Recognising the patterns thal disease takes allows us to understand what's at the root of a problem,
enabling accurate diagnosis. Followng up this understanding helps treatments to be devised and
preventative measures to be put in pla.
Much of pathology goes on behind the scenes which may account for the fact that many people are
almost unaware of its ongoing and vital contributions to modem medicine. Without the work of
pathologisls there could would be no evidence to support the diagnosis and clinical management of
disease, and improving or even maintaining the quality of medical care would be impossib.
The College'5 unique role ensures Ihat high qualtty slandards of knowledge and expertise are
rnaintained in all areas relating to pathology. The College ensures that pathologists are qualified and
up to date in their practice by..
Setting standards for education and training in pathology.
Examining against these standards.
Providing a leading continuing professional development programme.
Running scientific seminars. webinars and expert workshops on a national and regional
basis.
The College looks after the interests of patients by-
Producing guidellnes and othèr documents that sel standards of best pra¢ts'ce.
Making our case to parliamentarians through the Health Committee, All Party Health Groups.
individual ministers and civil servants to raise awareness of the role pathology plays in
providing safe patient care.
Ensuring lay representstion on all designated College commrttees.
Working with organisations such as Lab Tests On-Line and Labs Are Vital as a resour for
patients to provide information about the range of clinical tests that are used in their diagnosis
8nd treatment.
The College helps in Ihe search for cures to disease by committing to strengthening Ihe research
base of the specialty. This is achleved through..
Supporting fellows and trainees who undertake research aclNities as part of Iheir day-to-day
work.
Awarding bjrsaries and prizes for research.
Page 1
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
Objectives & activities (continued}
The College has a public engagement programme whose aims include inspiring secondary school
students to learn about science through an innovative and creative programme focusing on health
and disease. The goals ofthis programm8 are to..
Increase interest in pathology as a Career option.
Raise awareness of pathology and its cwcial role in treating and curing disease.
Contribute to the wder initiative of engaging the public in contemporary scien,
Support the teaching of science in secondary schools.
Change attitudes towards science, in particular pathology.
Activities
To achieve our objectives the College has undertaken significant actrvities during the year under
review..
Tralnlng, examlnations and assessments:
Setting the standards for training in pathology through the provision of medical, clinical
science and veterinary pathology curricula.
Administering tnedical pathology training thiough College Specialist Training Committees,
who advise and provide guidance on all rnajor issues relating to specialist training in
pathology.
Managing the development, implementation and evaluation of workplace-based
assessments for medical trainees and advising on the development of workplace-based
assessments for clinical science trainees.
Registering and monitoring Specialty Registrars for the duration of their training and
recommending them for the award of a Certificate of Completion of Training {CCT) to the
General Medical Council IGMC).
Providing electronic training portfolios to allow registered trainees to record their progress in
training.
Development, implementalion and delivery of the FRCPath Part 1 and Part 2 examinations
in the 17 pathology speciarties. as well as the Certificate and Diploma examinalions and the
Stsge A and Stage C BMS examinations.
Ensuring that curricula, assessments and examinations are approved by the appropriate
regulator, and that transitional arrangements are in place where these change significantly.
Rècommending to Ihe GMC whether or not the training andlor qualifications and experience
of pathologists applying lo the Specialist Register under the Certificate of EquNalence of
Specialist Registration (CESR) rules is equivalent in content and duration to that required for
a Certificate of Completion of Training.
Management of the review and approval of applications for Fellowship by published works.
Supporting training and continuing professional development through the provision of the
Pathology Portal.
Supporting the provision and promotion of pathology in undergraduate and foundation
training.
Patient safety
Support pathologists and their team5 to improve safety ar)d quality of care.
EncouTage shared learning to advance patient safety and quality improvement
Page 2
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
Aetivltias (continued)
Professional slandards
Deliver a leading continuing professional development scheme and user friendly online CPD
and revalidation pcrttolio for members.
Supporting the Professional Perforn)an Panel to deal wth revalidation queries and
concerns about professional performance in all disciplin8s of pathology.
Delivering invited reviews of pathology services for healthcare organisations and providing
formal advice on professional performan in pathology.
Supporting the ongoing oversighl of, and governance for, ext8mal quality assessment
stakeholders.
Consultancy services
The provision of ¢onsutsn¢y servi¢es to providers or Gommissioners Whe an authoritative
independent review is required on the provision of high-quality pathology services.
Cllnl¢al Effectlveness
Providing guidan and support to members and trainees on patient safety and quality
improvement melhodologies including clinical audtt and delwering continuous quality
improvement awarenes5 months.
Ensuring pathology input into guidelines and standards produced by national bodies
Continued memb&rship of the International Collaboration on Cancer Raporting to support the
production of common and internationally validated and evidence•based pathology datasets
for cancer reporting for use throughout the world.
The production of high-quality evidence based clini¢al guidelines in pathology to accredited
stsndards.
Hosting webinars for new guidance documents to support pathologist understanding and
apply them in practice.
Workforce
Maintaining standards in pathology by reviewng and approving consultant level job
descriptions and overseeing the College's statulory role in consumant advisory appointment
committees (AAC'S).
Collecting data from direct surveys and the outcomes of appointments to enable the College
to define the workforce required to deliver high qualty patient centred pathology services
throughout the UK.
Providing data to enable the College to have a clear voice on pathology workforce planning.
Conferences and academlc actlvlties
Management and development of the programme of in-house symposia and online webinars
designed to keep participants up to date with ¢urrenl thinking and practice in the pathology
disciplines.
Advisory committees
Much of the work of the College is achieved through the Col*'s committee structure
reporting to Council. These activities provide professional advioe and guidance through
specialty advisory committees, intercollegiate and joint committees.
Committees deal with generic matters crossing all pathology specialties whilst the spe¢i81ty
advisory committees advise on specialty specific matters such as histopathology and
mlcrobiology, etc.
Establishment of a network of lay advisors to input into specific committees.
Regional councils for Northern Ireland. Scotland and Wales maintain valuable regional and
local influence and insight.
Committees that report to the Trustee Board incILe Council, Nominations Committee,
Governance Committee and the Remuneration Committee.
Page 3
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
Activitios {continued)
Communlcations
Production of the quartedy publication -The Bulletin"distributed lo members and subscribers.
Production of a range of publications and guidelines on best practic8 in pathology.
Production of the monthly President's e-newsletter for members.
Development and maintenance of the College's web site, including the members, area.
Engagement wtth politicians, civil setvants and other key slakeholders across the UK to raise
awareness and understanding of the value of palhology and the role of the College.
Responding to parliamentary questions and consultations.
Identifying opportunities to promote the work of the College via the media and improve Ihe
understanding of pathology.
Providing a piofessional point of contad for all media enquiries.
Delivering the College's public engagement programme, including National Pathology Week.
Managing grant schemes and awards.
Internatlonal development
Providing support for the work of the Intematlonal Committeè, ehaired by the Clinical Director
of Interr)ational Activities. and the International Regional Advisors and Country Advisors.
Supporting current intemational medical graduates through provision of the College
sponsorship scheme and Medical Training Initiative, and the Intemational Tralnee Support
Scheme.
Supporbng future international pathologists throughout thèir cara8rs through the provision of
the International Pathology School.
Providing support for examinations and candidates based outside of the UK.
Providing support for refugee pathologists in the UK.
Providing reSoue$ for members and he8lth¢are workers in regions affected by challenge
and conflict.
Fostering intematlonal slrateglc partnershlps, collaborations and alliances through the
development of Memorandums of Understanding and delivering the work agreed.
Delivering Intèrnational Pathology Day annually.
Advocating and promoting Ihe role of the College intemationally, including through the
delivery of projects (e.g ARISE)-
Supporting the professional development of international members and trainees.
Raising awareness and understanding about the role and contribution of pathology to global
health.
Equallty. dlvotsity and inclusion (EDII
Hosting regular meetings of the EDI Nebvork to ensure EDI is embedded in all the College
dS
Developing an action plan to increase dNer5ity and ensure inclusion.
Progressing work to initiate a survey of member characteristics and barriers to engagement
to better inform the College's policies and procedures.
Hosting events to raise awareness of EDI matters and generale discussion.
Volunteers
Many members give their time freely to help the College achieve its objects by attending committee
meetings, sitting on working parties. acting as examiners, commènting on reports, a¢ling in a local
liaison capacity, assisting with the public engagement programme. or undertaking some other task
or function on behalf of the College. The Trustee Board is greatly Indebted to these individuals for
their commitment and support.
Page 4
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
Achievements & performance
The College produces a full Annual Report, which should be consulted for an analysis of thè
achievements and performance of the College for the year to 30th June 2022.
Investmont performance
The last 12 months were a tale of t0 contrasting halves. The second h8lf of 2021 was still cheerful
for markets, whereas the first half of 2022 destroyed value almost everywhere. In sterling terms, the
first period saw global equities rising 8.5 /0, whereas the second period witnessed a drop of 12.50/0,
for a net 12 month retum of -5 %. UK Govemment bonds showed something surprisingly similar in
direction, but much worse in outcome, wtth the ffirsl period up 0.6Yo and the second down -140/0 for
net 12 month retum of -13.5/0.
Inflation was the main econornic land human) issue throughout the whole period, with the UK CPI
jumping from 2.5Q/o to 9.10/0. Part of the increase was due to the Ukrainè war raising energy and fo¢Jd
pri$ across the world, but the inflationary surge had started well before that. Central banks
responded with le[ty, announcing plans to increase rates to levels sufficient to tame inflation. A
rther concern was recently added to investors, worry list: economic growLh.
Within equltles. thè value and growth styles tracked each other during the first half and then growth
collapsed during the second half. The energy, commodrties and defence sectors have soared in the
last 6 months whilst all other sectors fell sharply. Most of that move was due to circa 600/0 rise in oil
and gas prices caused by the Ukraine war. As the investment mandate is to ensure that securities
in the portfolio do not contravene the spectfic ethical requirements regarding direcl investment in
fossil fuels, mining, tobacco, and armaments, this has affected Ihe overall portfolio, resulting in a fall
in value over the last 12 months. However. over the longer tem) the investrnents have still delivered
good positive retums.
Financial review
The tolal income of the College amounted to £7.85 million, with expenditure of £7.35 million and a
resultant surplus of £499k. The investment portfolio decreased by £1.03 million, resulting in a deficit
for the year of £536k
Membership subscriptions continu8 to be the largest source of income, amounting to £3.97 million.
We measure our SUCSS by eMberShIp numbers, which stood at 12,500 at the beginning of the
financial year and 13,000 at the end. Income from postgraduate education and examinations
amountsd to £2 million compared to £2.2 million last year. The prior year was unusual in terms of
income as we were dealing with catch up as a result of Covid-19. effectively running an addrtional
examination sitting. Examination operations have now normalised, wrth candidate numbers
continuing to be strong. The College continued to hold many meetings virtually, this saving on travel
and accommodation costs.
Income from the trading activities of the College through the Events @ No 6 Conferen centre
amounted to £901 k, a considerable increase over thè prior year. Following the relaxation of the
restsiction5 that had to imposed because of the CovwJ-19 pandemic, the centre has bn able to
operate throughout the year, with bookings retuming slowly for the second half of 2021 and then
more robustly for the first half of 2022. Due to a strong performance in the last 3 months of the
financial year, the budget for the whole year has beèn exceeded. and bookings continue to hold up
well going foward. The decision to retain the sales and marketing staff so that we could be on the
front foot as the economy opened up was the right one. as we were able to respond quickly to
booking enquiries and convert these into firm contracted business. The tradin9 subsidiary currently
has a net deficit and the trustees anticipate it will return to surplus within the next 5 years.
Page S
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
Resebves
The Trustee Board has established a reserves policy. whereby the unrestricted fvnds not committed
or invested in tangible fixed assets, or designated for specific purposes {the 'free reserves,) held by
the College. should normally be sufficient to allow the College to operate without income for up to
15 months. This level of reserves is essential, because our income is not guaranteed and can be
subject to significant fluctuations year on year.
The College's reserves ensure that short temi changes in revenue will not malerialty affect the
College's activities, secures the long term funding of the College and enables the College to meet
its duties under statute and its Royal Charter to promote standards of education and practice of
pathology. This level of reserves would also enable the College lo address any unforeseeable ad-
hoc expenditure arising from topical issues in pathology, which the College feels should be
addressed. At 30th June 2022 the level of free reserves of £6.4 million equated to 10.6 months of
unrestricted expenditure. The total amount of restricted funds at 30 June 2022 amounted to £1.61
million. Total College funds amounted to £37.96 million.
Going concern
The trustees have reviewed the financial position and financial forecasts, taking into account th6
levels of investment reserves and cash. and the systems of financial control and risk management.
As a result of this review, the trustees believe that they are well placed to manage oprational and
fjnancial risks successfully.
Accordingly, the trustees consider that the College has adequate resour5 to continue in
operational existence for the foreseeable future. They continue to support the going concern basis
in accounting and in preparing the annual financial accounts.
Designated funds
Designated funds are funds set aside by the Trustee Board out of unrestricted general funds for
specific future purposes or projects and are excluded from the value of the College's free reseNes.
An explanation of Ihe College's designated funds is given in note 20 to these accounts. The l¢)tal of
designated funds at 30 June 2022 amounted to £29.56 million.
Investment policy and objectlves
The Trustee Board's investment policy is to maximise the retum on investments taking the rnedium
to long-term view with a moderate level of risk. The capital value of the portfolio should be protected
in line with the objective of generating an annual rate of return of inflation, as defined by the
Consumer Price Index (CPI). plus 4V• over a 5-year basis after expenses.
The Trustee Board may invest funds of the College in such stocks, funds, shares, or securities and
other investments within the United Kingdom or elsewhere as the Board sees fit, provided that the
Board is sab'sfied that such investment is not speculative and will not expose such monies and other
Investments to undue risk.
The Trustee Board has adopted an ethical investment policy precluding investrnent in fossil fuel,
tobacco, mining or armament companies. The portfolio is managed by an investment management
company. The total return approach where income and capital gains are considered in aggregate is
adopted, including for those investments relating to restricted funds.
Page 8
The Royal College of Pathologists
Rgport of the trustees for the yoar ended 30 Jung 2022
Risk management
The principal risks faced by the College relale to.. (al Covid-19, as this has affected most areas of
operation of the College and the finances substantially, including the loss of revenue from the
conference centre and how this will develop as Ihe economy op8ns up as th8 Covid-19 r8Strictions
are lifted,. {b> IT risks. including breach of security on systems, the failure to UFdate or innovale IT
8yStems, and reliance on the College database.. and {c) economic factors including inflation and thelr
impact on the costs of the College and the ability to match these with rising income streams.
The risks associated with Covid-19 are being mitigated by continuing to run committee meetings and
other events virtually or on a hybrid basis. ensuring technology is up to date to allow this to happen,
regular review by the trustee board, and by monitoring actual financial perfomiance closely against
the budget.
The risks associated with the conference centre are being mitigated by increasing marketing
activilies, and regular meeting5 With the contract Caterers who are responsible for the sales and
marketing of the space. The directors of the trading subsidiary company are meeting with them
monthly, and the operational staff meet weekly. This will highlight any issues as they occur.
The IT risks are mitigated by having replaced on-premises IT systems with cloud hosted technologies
and conducting regular reviews of equipment and soare. A review of the requirements for the
College including the database has commenced, and a technology transformation steering group
has been established that reports directly to the trustee board to oversee the governance and
progress of this significant project.
Auditors
A resolution will be proposed at the Annual General Meeting that Begbies be re-appoinled as
auditors to the College for the ensuing year.
Plans for future periods
Trustees have agreed a new strategy for 2021-24 that has 5 strategic aims.
strategic aim 1- to support all members through the delivery of high-quality member services.
This will be achiaved by..
Supporting current members in their continuing education by offering guidance and support.
Encouraging future members by fostering their interest in a career in pathology and
supporting career development.
Promoting and encouraging inclusivity and diversity throughout our memtership, the wider
profession and our work.
Advancing knowledge in pathology through the delivery of a range of resources to support
continuing professional development for all our members.
Implementing the use of technology that widens and improves consistency of access to
s&Nlces for members.
Strategic aim 2 - develop and maintain high standards of education, training and research across
all pathology specialties.
This will be achieved by..
Providing curricula, assessments and examinations for professional groups, ensuring that
they meel the future requirements for the profession.
Optimising the efficiency of the examination process by developlng centrallsed systems and
providing enhanced support to examiners.
Page 7
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
Plans for future perlods (contlnued)
Increasing international participation in College examinations.
Encouraging and supporting our members and trainees to undertake and publish htgh-quality
research to advance the PTactice of pathology.
Strategic aim 3 - promote excellence and advance knowledge in pathology practice across all
speciallies.
This will be achieved by:
Advocating for a properly resourced, supported and sustainable pathology workforce.
Continuing to develop excellent contilluous professional development iecording and support
services.
Delivering high-quality resources to benefit pathology practice.
Developing a robust fiamework for governance and oversight of external qualily assurance
to ensure high standards.
Promoting environmental sustainability in pathology and the ways in which we work.
Supporting future innov*ion and delivery of digital resources in pathology.
Strateglc aim 4- increase the College's influence through a clear, coherent. professional vol.
This will be achieved by:
Promoting the College as a vttal contributor to health policy and decision making.
Influencing policy to advance palient care and safety.
Championing the College as the leading medical royal college in genomics seNices_
Promoting pathology to the wder health professionals and the public to enhance our capacity
and influence policy.
Strategic aim 5- resourcè the future development of the College.
We wlll achieve this by=
Increasing and devèloping new sources of income to support the work of the College.
Delivering effedive management of member services and providing an excellent place to
work.
Building corporate Memr$hIp that benefits the College and its member partners.
Structure, Governance & Management
The College of Pathologists was founded on 21 June 1962 and was in¢orporate(l under Royal
Charter on 28 February 1970 and registered as a Charitable Trust on 28 April 1970. The College is
governed by its Royal Charter, Ordinances and By-laws, the "governing documents".
The Trustee Board is responsible for the structure, governance and management of the College,
including financial matters. Members of the Board are the trustees of the College. Committees
reporting to the Trustee Board include the Council, Govemance Committee, Nominations Committee
and Remuneration Committee. Council is responsible for the clinical, educational and professional
functions of the College. Council has sub committees. including standing advisory committees,
éxaminations and training committees, and regional councils.
The trustees who served during the year are sel out below. They comprise the 7 h¢)norary officers,
the chairs of each of the regional councils for Northern Ireland, Scotland and Wales. and 3 lay
trustees. Trustees are elected or appointed for a thre&year term ofoffice after which they may see
again only after a one-year gap, unless elected to another honorary officer role. The Treasurer,
Registrar and lay trustees can seNe fr)r consecutive three-year terms of office.
Page B
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
Structure, Governance & Management (contlnued
The honorary officers are elected by the fellows and diplomate members as a whole from amongst
the fellows. The chairs of the regional councils are elected by the fellows and diplomate members in
thal region from amongst the fellows resident within the particular region. The three lay twstees 8re
appointed following a process which includes advertising these positions, completion of an
application form, shortlisting against the requirements contained in the role description and person
specification, and a panel interview.
Trustees take decisions in the best interests of the College as a whole. They operate in accordan
with a code of conduct that makes explicit reference to objectivity in decision-making. A regisler of
interests is maintained in respect of each member of the Trustee Board and Council. On appointment
to office trustees receive an induction pack and are invrted to attend the annual induction training
meeting.
The Trustee Board approves the College's annual budget and fotward plan. Once approved, the
implementation of the plan is delegated to the staff. who have the authority to work within the
parameters set by the Board. Decisions of a strategic nature, or items oulwilh the agreed budget
and plan, musl be referred to the Board.
The College wholly owns a subsidiary company, RCPath Trading Limited. which undertakes certain
trading activilies. The directors of the company are the College's President, Treasurer, Chief
Executive, and an independent director appointed by the College's Trustee Board. The Truslee
Board requires that the taxable profrts of the company be paid to the College under gift aid.
Responslbllltles of the trustees
The trustees are responsible for preparing the report of the trustees and the financial statements in
accordance with applicable Saw and Unlled Kingdom Accounting Standards (United Kingdom
Generally Accepted Accounting Practice).
The law applicable to charities in England and Wales requires the trustees to prepare financial
statements for each financial year which give a true and fair view of the stat8 of affairs of the College
and of the incoming resources and application of resources of the College for that period. In
preparing these financial statements, the tnjstees are requlr8d to..
Select surtable accounting policies and then apply them consislenlly;
ObseNe the methods and principals of the Stslement of Recommended Practiek (Charities
SORP).,
Made judgements and estimates thal are reasonable and prudent-
state whether applicable accounting standards have been followed, suty-ect to any matsrial
departures disclosed and explained in the financial statements., and
Prepare the financial statements on the going concern basis unless it is inappropriate to
presume that the College wll continue in operation.
The trustees are responsible for keeping proper accounting records that disclose with reasonable
accuracy at any lime the financial position of the College and enable them lo ensure that the financial
statements comply with the Charities Act 2011. the Charities SORP (FRS 102) and the provisions of
the Royal Charter, Ordinances and By-Laws. They are also responsible for safeguarding the assets
of the College and hence for taking reasonable stsps for the prevention and detection of fraud and
other irregularities.
The trustees are responsible for the maintenance and integrity of the College and financial
information included on the College's websile. Legislation in the United Kingdom governing the
preparation and dissemination of financial ststements may differ from legislation in other
juris¢Jictions.
Page 9
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
Structure, Governance & Manag8ment {continued)
Key management personnel remuneratlon
The trustees Gonsider the Trustee Board and the senior management téam comprise the key
managemenl personnel of the charity in charge of directing and controlSing, running and operating
the College on a day to day basis. All trustees give of their time freety and no trustee received
remuneration in the year. Details of trustees, expenses are disclosed In note 6 to the accounts.
The pay of all staff, including the senior staff, is reviewed annually by the remungration committee.
Pay is benchmarked against the median of the range for similar roles in similar sized organisations
in the London not for profft sector. Remuneration is based upon eight pay bands each with five pay
points. Staff progress up the pay scale on successful complelion of an annual perf0rrnan review.
The senior management team meet annually to review and agree perf0mlan review summaries
for all staff. and the remuneration committee reviews and ratrfies this decision. The remuneration
eommfftee revlews the performance reviews for all of the members of the senior management team
and agrees their progression up the pay scale. No employee of the College or of its contractors is
paid below the London living wage.
ststement of disclosure to auditor
So far as the trustees are aware, there is no relevant audit information of which the College's auditors
are unaware. Additionally. the trust$ have taken all the steps they ought to have taken as trustees
in order to make themselves aware of any relevant audit information and to establish that the
College's au(Jilors are aware of that information.
Referonce & administrative detalls
Trustees
Those who setved as truslees during the year were as follows..
Dr Andy Boon
Prof Sarah Coupland
Dr Bernie Croal
Prof Angharad Davies
Ms Jill Gauntlett
Dr Anila Hill
Prof Peter Johnston
Dr Jonathan Kell
Dr Elijah Matovu
Dr Gareth McKeeman
Prof Ken Mills
Dr Stephen Morfey
Prof Mike Osborn
Dr Lance Sandle
Mr Robert Smtth
Mr Vincént Voon
Dr Esther Youd
Treasurer
Vice President
Chair. Scodand regional council
Vice President
Lay Trustee
Co-opted Trustee (appointed 18 November 2021)
Vice President
Chair. Wales regional council
Co-opted Trustee (appointed 18 November 20211
Chair, Northem Ireland regional council (appointed 18 November 20211
Chair, Northem Ireland regional council {demitted office 18 November 2021}
Assistant Registrar {appointed 18 Novanber 2021)
President
Registrar
Lay Trustee & Chair of Trustee Board
Lay Trustee
Assistant Registrar {demitted office 13 octob 20211
Page 10
The Royal College of Pathologists
Report of the trustees for the year ended 30 June 2022
Reference & admlnlstratlve detalls (continued)
Senlor Stsff
Daniel Ross
Joanne Brinklow
Diane Gaston
Nigel Pollard
Kalherine Timms
Chief ExecutNe
Director of Learning
Director of Communication5
Director of Corporate Services
Direetor of Professionalism
Principal Office
The Royal College of Pathologists, 6 Alie Street, London E18QT.
Telephone= 020 74516700
E-mail: info@rcpalh.org
Website.. ww.rcpath.org
Registered charity number 261035 in England & Wales
Company registration number RC000127
Professional advlsors to the College
Auditors:
Begbies, 9 Bonhill Street, London EC2A 4DJ.
Taxation advisors:
Crowe, 55 Ludgate Hill, London EC4M 7JW.
Property advisors:
CBRE, Henrietta House, Henrietta Place, London W1G ONB.
Sollcltorg:
Womble Bond Dickinson, 4 More London Riverside, London SE12AU.
Investment managers:
Canaccord Genuity, 41 Lothbury, London EC2R 7AE.
Bankers:
HSBC, 69 Pall Mall, St. James's, London SW1Y 5EY.
Approved by the Trustee Board and signed on their behalf by..
Professor Mike Osborn
President
4 August 2022
Page 11
Independent auditor's report to the trustees of
The Royal College of Pathologists
Oplnlon
We have audited the financial statements of The Royal College of Pathologists (the '¢harity'l for the
year ended 30 June 2022 which comprise the Consolidated Statement of Financial Activities, the
Consolidated and College Balance Sheets, the Consolidated Statemenl of Cash Flows and notes to
the financial statements, including a summary of significant accounting policies. The financial
reporting framework that has b86n applied in their preparation is applicable law and Unrted Kingdom
A¢counting Standards, including Financial Reporting Standard 102 The Financial Reporting
Stsndard applicable in thè UK and Republic of Ireland {United Kingdom Generalty Accepted
Accounting Practice).
In our opinion th8 financial 5tatements-
Give a true and fair view of the state of the parent charity and its subsidiary undertaking's
affairs as at 30 June 2022 and of their incomlng resources and application of resources, for
the year Ihen ended-,
havé been properly PTepared in accordance with United Kingdom Generally AcGepted
Accounting Practi.,
have been prepared in accordance with the requirements of the Charities Act 2011.
Basis for oplnlon
We conducled our audit ill accordan with International Standards on Auditing (UK) IISAS {UK))
and applicable law. Our responsibiltties under those standards are further discussed in the auditor's
responsibilities for the financial statements section of our report. We are independent of the charity
in accordance with the ethical requirements that are relevant to our audit of the financial statements
in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other ethical
responsibilities in accordance with these requirements. We believe that the audit evidence we have
obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating lo golng concern
In auditing the financial ststements, we have concluded that the directors, use of the going concern
basis of accounting in the preparalion of the financial slatements is appropriate.
Based on the work we have perforffled, we have not identified any material uncertaintie5 relating to
events or condrtions that, individually or collectively, may cast significant doubt on the Company's
abilty to Continue as a going concem for a period of at least Iwelve months from when the financial
statements are authorised for Issue.
Our responsibiltties and the responsibilities of the directors wth respect to going concem are
described in the relevant sections of this report.
Other infonnation
The trustees are responsible for the other information. The olher information Comprises the report of
the trustees. Our opinion on the financial statements does not cover the other informalion and,
except to the extent othemise explicitly stated in our report. we do not express any form of assurance
conclusion thereon.
In connection wth our audit of the financial statements, our responsibility is to read the other
informats'on and. in doing so, consider whelher the other information is materialty inconsistent with
the financial statements or our knowledge obtained in the audit or otherwise appears to be materially
misstated. If we identtfy such material inconsistencies or apparent material misstatements. we are
required to determine whether there is a material misstatement in the financial statements or a
material misstatement of the other infomiation. If based on the work we have perfomed, we
conclude that there is a material misstatement of this other infornation, we are required to report
that fact.
We have nothing to report in this regard.
Page 12
Indep&ndent auditor's report to the trustees of
The Royal College of Pathologists
Matters on whlch we are required to report by exceptlon
In the light of the knowledge and understanding of the charf(y and its environment obtsined in the
course of the audit. we have not identified any material misstatements in the report of the Irustees.
We have nothing to report in respect of the following matters in relation to which the Chartties
(Accounts and Reports) Regulations 2008 require us to report to you rf, in our opinion..
The information given in tha trustees, report is inconsistent in any material respèct wilh the
financial statements: or
Sufficient accounting records have not been kept- or
The financial statements are not in agreement with the accounting records.. or
We have not received all the information and explanations we require for our audit.
Responslbilities of trustees
As explained more fully in the trustees, responsibilities statement, the trustees are responsible for
the preparation of the financial statements and for being satisfied that they givé a tru8 and fair view.
and for such internal control as the trustees determine is necessary to enable the preparation of
financial statemenls that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the trustees are responsible for assessing Ihe charity's abiltty
to continue as a going concem, disclosing, as applicable. matters relating to going concem and using
the going concern basis of accounting unless the trustees either intend to cease operations, 01 have
no realistic altemative but to do so.
Audltor's responslbllltles for the audit of the financial statements
We have been appointed as audilors under section 151 of the Charities Act 2011 and report in
accordance with the Act and relevant regulations made or having 8ffect thereunder.
Our objectives are to obtain reasonable assurance about whether the financial statements as a
whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's
report that includes our opinion. Reasonable assuran is a high level of assuran, but is not a
guarantee that an audit conducled in accordance with ISAS (UK) will always detect a malerial
misstatement when it exists. Misstatements can arise from fraud or error and are considered material
if, individually or in the aggregate, they could reasonably be expected to influence the economic
decisions of users taken on the basis of these financial statsments.
Extent to which the audlt was capable of detectlng Irregularltles, Including fraud
Irregularities, including fraud, are instances of non-compliance wrth laws and regulations. We design
procedures in line with our responsibilities, outlined above, to detect material misstatemenls in
rèspect of irregularities, including fraud. The extent to which our procedures are capable of deteding
irregularities, including fraud is detailed below:
Agreement of the financial statement disclosures to underlying supporting documentation,.
Enquiries and confimialion of management and the trustees as to their identification of any
non-compliance wilh laws or regulations, or any actual or potential claims.,
Review of minutes of Board meetings throughout the period.,
Incorporating unpredictability into the natuie, liming andlor extent of testing-,
Evaluation of the selection and application of the accounting policies chosen by the charity,.
In relation to Ihe risk of management override of internal controls, by undertaking procedures
to Teview joumal entries and evaluating whether there was evidence of bias that represented
a risk of material misstatement due to fraud.. and
Page 13
Independent auditor's report to the trustees of
The Royal College of Pathologlsts
We assessed the susceptibilty of the charity's financial statements to material rnisstatement,
including how fraud might occur by considering the key risks impacting the financial
statements.
Our audit procedures were designed to resporKI to risks of material rnisstalement In the financial
ststements, recognising that the risk of not detecting a material misstatement due to fraud is higher
than the risk of not detecting one resulting from error, as fraud may involve deliberate ConclMent
by. for example. forgery. misrepresentations or through collusion.
There are inherent limitations in the audit procedures performed and the further removed non-
compliance with laws and regulations is from the events and transactions reflected in the finanaal
statements. the less likely we are to become aware of it.
A further descripiion of our responsibilities for the audit of the financial statements is located on the
Financial Reporting Council's website at. www.frc.org.uklauditorsresponsibilities. This description
foms part of our auditorfs report.
Use of our report
This report is made solely to the College's trustees, as a btsty, in accordance wth part 4 of the
Charities (Accounts and Reports) Regulations 2008. Our audtt work has been undertaken so that we
might state to the College's trustees those matters we are required to state to them in an auditorfs
report and for no other purpose. To the fullest extent pemiitted by law, we do not accept or assume
responsibility to anyone other than the College and its trustees as a body. for our audit work, for this
report, or for th8 opinions we have fomied.
Begbies
Chartered Accountants
Statutory Auditors
9 Bonhill Str8et
London
EC2A 4DJ
Begbies is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.
Page 14
The Royal College of Pathologists
Consolidated Statement of Financial Activities for the year ended 30 June 2022
Unreslricled Unreslricled
Total
General
De5vJnaled
Funds
Funds
Funds
2022
Total
Funds
2021
Restricted
Funds
Income from-
Note
Donations & legacies
Charitable activities
588
1,483
Subscriptions
Poslgraduale education & examinations
Pathology portal
Inlernalional devek)pment
Conferences & academic activrties
Professional standards
Research
Communications & publ engagement
Trading activitses
Investments
3,974,297
1.981.094
3,974,297
1,994,594
50D,000
45,239
190,467
57,844
40,000
115
3,785,867
2,199.501
175,000
14,316
262,107
52,626
13,500
500,000
10,021
35,218
190,467
57,844
40,(K)O
115
423
901,377
77.614
65.253
1.371
79.477
65,253
68,324
93,946
79,820
1,863
Other
Total Income
7.283,867
565,384
7,849,251
6,733,413
Expendlture on:
Raising fvnds
Tradiw actllIeS & educatlon centre
Investment management
Charitable activities
1.350.735
41.682
1,154
50,297
1,402,186
41,682
946,270
23.557
Poslgraduale education & examinal#)ns
Pathology portal
International development
Conferences & academi¢ aclivrties
R8s8arch
Professional standards
Clinical effectivenÈs$
Workforce
Communications & publK engajemenl
Advisory coMmittS
Total expendlture
Included in the above expenditure is
£121,623 relats'ng lo noTrrecLtrrenl
IT costs
2.202,
2.202,566
160,987
359,539
415,176
1.750,826
138.871
360,670
354,816
3.462
269,543
259,300
313,000
1,096,090
413,749
5,930,154
160,987
16,342
24,668
343.197
390,508
361,753
365,192
378,239
1,217,789
436,080
361,753
372,960
378,239
1,218,610
436.080
7,349,778
7.768
821
7,087.741
8,922
253.115
11
Net income I (expenditure) before
net gains on inveslmonts
Nel Ilossesl I gains on investsnenls
Nel Income I lexpendlture
Transfers belween funds
196,126
18,922)
312,269
499,473
803.259
14
1874,sW>
1678,838}
{129,7531
1160,984} 11.035.948)
151,285
1536,475)
1,035.623
1,838.882
18,9221
128,753
19
1,C¥JO
Net movement In funds
{808,5911
119.831
152,285
1536,475)
1,838,882
Reconciliation of funds-
Total fijnds tght loard
Total funds carriod forward
7.596.098
29,436,817
1,458.634
38,491,549
36,652,667
37,955,074 38,491,$49
19
6,787,507
29,556,648
1,610,919
All of the above resulls are derived from continuing activities. There were no other recognIs gains or losses other
than those staled above.
The notes on pages 18 to 32 form part of these lunts.
Page 15
The Royal College of Pathologists
Consolidated and College Balance Sheets as at 30 Junè 2022
Consolidated
2022
2021
College
2022
2021
Note
Fixed Assets:
Tangible assets
Investments
13
14
37,777.416
5,233,165
38.403,585
6,294,113
37,777,416
5,233,265
38,403,585
6.294.213
Total fixod assets
43,010.581
44.697,698
43,010,681
44,697,798
Current assets:
Sto¢k$
Debtors
Cash at bank and in hand
15
16
4.489
803,693
7.066.834
4,900
477,465
6,143.921
4,489
1,137,333
6.822,340
4.900
844,610
6,138.929
Total current assets
7.875.016
6.626,286
7.964.162
6.988.439
Liabilities:
Credtiors-. Amounts falling due
within one year
17
14,607,566)
14,040,079)
{4,277,2291
13,958,939)
Net current assets
3.267.450
2.586.207
3,686,933
3,029,500
Total as$et8 less current liabilities
46,278.031
47,283,905
46.697.614
47.727.298
Creditors.. Amounts falling due
after more than one year
17
18.322.95n
18.792,3561
18.322.957)
18.792.356}
Totsl net assets
37.955.074
38,491,549
38.374.657
38.934,942
The funds of the College:
Unrestricted funds- general fvnds
Unrestricted fvnds- designated funds
Restricted funds
21
21
21
6.787.507
29.556,648
1.610.919
7.596.098
29,436,817
1.458.634
7.207.090
29,556.648
1.610.919
8,039.491
29.436.817
1,458.634
Totsl College funds
37.955,074
38,491.549
38.374.657
38,934.942
Th8 notes on pages 18 to 32 fom part of these accounts.
The financial statements were approved by the Trustee Board on 4th August 2022 and signed on behaff of the Trustee
Board by
Professor Mike Osborn
President
DrAndrew Boon
Treasurer
Page 16
The Royal College of Pathologists
Consolldated statement of cash flows for the year ended 30 June 2022
2022
2021
Cash flows from operatlng actlvltles".
Net cash provided by I (used in) operatlng activtties {nole 1 below)
Cash Ilows from Investlng actlvlt19S'.
Dividends and interest received
Purchase of property, plant and equlpment
Proceeds from the sale of investments
Purchase of inve8tmenls
1.375,059
1,190,575
79,477
161,4861
1.536,205
{1,382,3521
93,946
139,688)
1,529,147
11,680,003}
Net cash provlded by I (used In) Investlng actlvltles
171,864
196,598}
Cash 1104v8 from flnanclng actlvltles
Repayment of borr(wing
Cash inflows from new borrowing
Net cash provided by l (used in} financlng activltles
1495,9791
1326,503)
1495,9791
1326.503)
Chare in cash and cash equivalents in the year
1.050,942
767,474
Cash and cash equivalenls al the beginning of the year
6.148.220
5,380,746
ash and cash gqulvalents at the frnd of thg yoar {note 2 below)
7,199,162
6,148,220
Notes to the statement of cash flows
1. Reconciliation of net Incomellexpenditure) to net cash flow from opèrating actFVities
2022
2021
Net incomellexpenditurel for the year las par thè stat•m•nt of flnancial activiti•sl
1536,4751
1.838.882
Adjustment8 for:
Depreciation charges
IGainslAosse5 on investments
Dividends and interest
Ilncreaselldecrease in stocks
Ilncieaselldecrease in debtors
Increaselldecrease} in creditors
687,635
1.035,948
179,4771
(4111
1326,2281
594,C67
672.584
(1,035,623)
193,9461
6.331
86.745
{284,3981
Net cash provlded by l {usod Inl operating a¢tivitigs
1,375.059
1.190.575
Z Analysis of cash and cash 4uivalents
2022
2021 Change in year
Cash al bank
Cash al broker
7,066,834
132,328
6,143,921
4,299
922.913
128,029
Total cash and cash equÉvalenls
7,199,162
6,148,220
1,050,942
Analysis of changes in net debt
2022
Cash fbws
2021
Cash
Cash at broker
Loans falling due withiri one year
Loans falling due morè than one year
7,066,834
132,328
1291.2501
8,322 957
1,415,045
922,913
128.029
26.580
469,399
1,546.921
6,143,921
4,299
1317,e30)
8,792.356
2.*1.966
Page 17
The Royal College of Pathologists
Notes to the Financial Ststements as at 30 June 2022
1. Accounting poll¢i05
{a} Basis of preparation
The financial slalement8 have been prepared in accordance wlh the Statement of Recommonded Practice..
Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard
applicable in the UK and Republic of Ireknd IFRS 102) issued on 16 Juty 2014 and the Financial Reporting Standard
applicable in the UK and Republic of IreL8nd IFRS 102) and the Charities AGI 2011 and UK General Accepted
Practice as It applies from 1 January 2019.
{bl Publlc beneflt antlty
The College meets the definltion of a public benefit enlty under FRS 102.
(GI Golng Concgrn
The trustees consider that there are no material uertalntieS about the College's abilty to conllnue as a going
concem.
The trustees do not wnsidor that there are any sources of estimatn un¢ortainty at the reporting date that havo a
significant risk of causing a material adjustment to the carying amounts of assets and liabilities within the next
reporting perh)d.
Idl Group financial statements
The financial slalemenls consolidate the results of the Col*e and ils wholly owned subsidiary, RCPalh Trading
Limited, on a line by line basis.
le} Income
Income is included on a receivable basis. Income from subscriptions, trainee registration and fees lor participation
in the continuing professional development scheme are recognised in the accounting period to which the services
covered by those fees relate. Fees recewed in advance are accounted for as delerred income wthin creditors.
Income from examinations and conferences & xadgmic activilv&s are included in the acwunling period in which
the examinab'on or conference lakes place.
{fj Expenditurè and irrgcoverablfr VAT
Expenditure is COgnised Once there is a legal or constructwe obligation to make a paymènt to a third p8ty.
il is probable that settlement will be required and the amount ol the oblKJ81ion can be measured reliabty.
Expenditure on charriable activities includes the costs of delivering examinations, training and educational activities
undertaken to further the purp¢)ses of the College and their associated support costs.
Irrecovorable VAT is charged as a cost against the activty for which the expenditure was incurred.
(gi Allocation of support costs
Resources expended are allocated to the particular 8Ctivty where the cost relates directly to that activjty. How8ver,
the cost of overall direction and administration of each activty, compri3ing the salary and overhead costs of the
canlial function, is apportioned, based on staff numbers engaged in each &tiwty. Govemance costs are apportK)ned
on the same basis.
{h) Forelgn currencies
Transactk)ns domin3ted in fore4n eurrencles are translated Into steding al the rate of ex¢hang& prevailing at the
lime of the Iransaclion.
Page 18
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
l)1 Tanglble ftxed a88ets and depreciation
Tangible fixed assets costing morg than £1,000 are capilalised. Depreciation is charged on fed assets al
rates calculated to wrf(e off their cost evenly as follows=
Freehold buikling$
over 50 years to residual value
Land
not depreciated
Fixtures. fitts'ngs and office equipment
over 3 to 5 years
Computer systems and Soare
over 2 to 5 years
The College has adopted an accounting poliw ol Gaprtalising borrowing $1$ that are directly attribUtsb lo the
construction of the new building. From the date of occupation of the premises in November 2019 interest has be8n
charged to the Statement of Financial Activit$.
As explained in note 14, heritage assets have not been GapitalK8ed or depreciated as no ielkgble Wdlue can be
attributed.
lj'l Operatlng lease8
Inslalments under operating lease commitmenls arising in the year are included in the Statement of Financial
Aetwities for the year in which they arise.
Ik) Stocks
These are ststed al the lower of eosl and net realisable value.
(11 Funds accounting
Funds held by the College are:
Unrest17¢1ed gengral lunds - these are funds which can be used in accordance wih the charitabl8 objects al the
discretion of the Trustee Board.
UnTrstncled Design8led funds - these are funds set aside by the Trustee Board out of unrestricted general funds for
specrfic future purposes gr projects.
Reslncled funds - these are funds that can only be used for pgrtiwlar tricted purposes within the 0.e¢l8 of th8
College. Restrictions aris8 I8n Sprried by the donor or where funds are raised for particular restricted purposes.
Further explanalbn of the nature and purpose of ea¢h fund is included in the notes lo the acttjunls.
(ml Pension schgmgs
The College participates in 2 pensbn schemes.. the defined benefit scheme, operated by SAUL (Superannuation
Arrangements of the UnNersty of London) and the defined contrtbutlon scheme operated by Royal London.
For SAUL, the actuarial waluation applies to SAUL as a whole and does not enIfy surpluses or deficits applicable
to indivu81 employers. As a whole, the market value of SAUL'S assets 8131 March 2020 was £3.612 millM)n
representing 940A of the liabilities. The market value of SAUL'S assets at 30 April 2021 was £4.369 million representing
1090k of the estimated liabiltties. 11 is not possible to identify an individual Employerfs Share of the undertying assets and
liabilities of SAUL. The College accounts for its participation in SAUL ag if it were a define(I contribution scheme and
pension costs are based on the amounts aclualty paid li.e. cash amount51 in accordance with paragraphs 28.11 of
FRS 102. Although there was a Technical Provisions deficit at 31 March 2020, allowing for post valLJaliDn oxperienGe
to 30 April 2020, SAUL had a Technical Provisions surplus. Therefore no deficit Gonlributions were required following
the 2020 valuation and there is no defined benefrt liability {i.e. the present value of any def11 contiibuts'ons du8 to
SAUL) lo be recognised by the College.
For the Royal London scheme, the pension charge represents the contributions payable by the College.
Inl RosgarGh grants
Grants payable and recehjable are reeognised in the slalement of financial activities in the p6ri0d to which the grant
relates and where conditions relating to the grant have been fulfilled.
lo) Temlnatlon payments
Tem)inatK)n payments are recognised in the Stalem¢nt of Finala1 Adivf(ios when incurred.
Page 19
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
(pl Fixed asset Invèstm9nts
Fixed asset investments a included al their fair values (market value) at the balance sheet date. Any gain or loss on
revaluation is tsken to the Statement of Financial Activities.
{qi Debtors
Trade and other debloTS are recognised at the settlement amount due after any tr&Je discount offered. Prepayments
are valued al the amount prepaid net of any trade discounts due.
{r) Cash at bank and in hand
Cash at bank and cash in hand includes cash and short temi highly liquid investments with a short malurity of three
monlhs or less from the dale of acquisition or t)pening of the deposit or simiiar account. Cash balances exclude any
fvnds held on behalf of service users.
Is} CredltOTS and prov581on8
Creditors and provisions are recognised where the Charity has a present obligation resulting from a past event that will
probably result in the transfer of fijnds lo a third party and the amount due lo settle the obligation can be measured or
estimated reliably. Creditors and provisions are nom)ally recognised at Iheir settlemenl amount after allowing for any
trage discounts due.
The charity only has finan¢ial assets and financial liabilities of a kind that qualify as basic financial instnjments.
2. Trading Incomo and gxp•nditure
RCPath Trading Limited
The College owns 1 000% of RCPath Trading Limited (Company number 045352961. The main activities of the ccthpany are
to undertake various trading activities of the College. The company supplies consultancy services under the trading name
of RCPath consulting. and operates a commercial conference centre called Evenls@No6 at the College's Alie Street
premises. The laller operation commenced in January 2019 and has made some losses to dale in rfs startp situation. It
will donate future taxable profits lo the College under gift aid. Trading results extracted from ils audited accounts are as
follows..
2022
2021
Profit & Loss account
Tunv)ver
934,310
1910,5011
23,809
68,325
1274,9091
1206,5841
Cost of sales and &Jministralive expenses
Nel profil I ILoss)
Payable under gift aid to The Royal College of Pathologists
Profft I (Lossl retained in RCPalh Trading Limited
23,809
1206,5841
Balance sheèt
2022
2021
Debtors
Cash at bank
259,550
244,495
504,045
1330,3371
173.708
{593,1901
{419,4821
100
1419,5821
1419,482}
19,402
4,993
24,395
{81,1391
{56,7441
386.5471
1443,291}
100
{443.391)
{443,2911
Creditors.. amounts falling due within one year
Net current assets
Creditors.. amounts falling due after more than one year
Net assets I Iliabililiesl
Share capitsl
Profit and loss account
Capital and ieserves al 30 June
The College has agreed a fomal loan to financially support 11$ trading $ub$ldiary ¢ompany's losses during the start-up
phase of its conference centre operations. The loan is for a period of up to 10 years.
The College purchased £32,933 {2021 - £Nill of services from its wholly owned subsidiary during the year and received
a payment of £17,50012021- £Nill towards the cost of shared overheads. Interest on the loan amounting 10 £10,419
{2021- £7.5821 was payable by the subsidiary company to the College. In accordance with the SORP, these transacts'ons
have been removed on consolidation.
Page 20
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
3. Dotsilod comparatives for the statement of financial activities in 2021
Unrestricted Unreslriclgd
General DesKJnaled
Funds
Funds
Total
Restricted
Funds
Fund$ 30 June 2021
Income from:
Donations & legacies
Charitable activi(ies
1,483
1,483
SubscriplDns
Poslgraduale eduGalion & examinatM)ns
Digital education project
International development
Conferences & acadern activities
Professional standards
Communications & publie engagemenl
Trading aclimlies
Investments
3,785,867
2.194.501
3.785,867
2.199,S01
175.000
14,316
262,107
52,626
423
5,0
17S,000
14,316
262,107
52,626
423
68,324
91.757
79,820
68,324
93,946
79,820
6.733.413
2.189
Other
Total income
6,551.224
182,189
Expendlture on:
Raising funds
Trading aclNilies
Investment management fees
Charitable actNities
945,670
23.557
600
946.270
23,557
Poslgraduale education & examinations
Digital education project
Intemational development
Confer8nces & academic aclivrties
Research
Professional standards
Clinical effectiveness
Workforce
CommunicatKffis & public engagement
Advisory committees
Totsl expendlture
1,737,826
13,000
138.871
5.000
91.943
3,462
1.750.826
138,871
360,670
354,816
3,462
269.543
259,300
313,000
1,096,090
413,749
355,670
262,873
269,543
251,717
313,000
1,095,270
391.165
7,583
820
22,584
5.646,291
30,767
253.096
5,930,154
Net incomg 11gxponditurel before net
gains on investments
Net gains on investments
Net Incomo I lexpendlture}
Transfe between funds
904.933
871,548
{30.7671
{70.907)
164,075
803,259
1,035.623
1.776,481
1604,4201
1.172.lJ81
{30.7671
603.420
93.168
I,OL)O
1.838.882
Net movement In funds
572.653
94.168
1.838,882
Reconclllatlon of funds:
Total funds brought forward
Total funds carriad forward
6.424,037 28.864,164
7.596,098 29.436,817
1,364,466
36.652,667
1,4S8.634
38,491,549
Pagè 21
The Royal College of Pathologists
Notss to the Financial Ststements as at 30 June 2022
4. Income from investments
2022
2021
Bank deposit interest
Income from listed investments
Income from investment properties
5.633
55,209
18,635
6,164
58,487
29,295
79,4TI
93,946
5. Donations & Logacios
2022
2021
College members
other donations
850
633
588
1.483
6. Staff costs. trustse remuneration and expenses, and the cost of koy manag•ment personnel
2022
2021
The total cost of salariès and wages were
Salaries W8$
Redundancy and temination costs
Social security costs
Pension contributions
2,644.301
21.500
280,500
337,846
2,391.857
238.755
328,813
3,284,147
2,959.425
The redundancy and lerminalion costs were settled and paid at the balance sheet dale.
The numbor of employees Nthose emoluments exceeded £60,000 in the year was as follows:
2022
No.
2021
No.
£70,001- £80,000
£80,001- £90.000
£120,001- £130,000
£130.001- £140,000
Contributions were made to a defined benefit pension scheme amounting to £74,*912021- £57.9681 in respect of the
staff noted above.
The key management personnel of the charity comprise the trustees, Ihe Chief Executive and the 4 (2021- 31 other senior
managers. The total ernpbyee remuneration of the key management personnel amount to £578,761 (2021- £465,6661-
The charity trustees were not paid cr received any other benefi15 from employment with the charity in the year
12021- £Nill. No charilytrustee received payment for professKJnal or other services supptied to the charity12021- £Nill.
Travel, subsistence and accommodalion costs incurred amounting to £20,71912021- £2091 were reimbursed to 13
12021 - 21 members of Ihe Trustee Board.
Details of the transactions with the Irading subsidiary are included in note 2.
During the year th8re wer8 no other related party transaclions {2021- £Nil).
Page 22
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
7. Staff numbèrs
The average number of employees {head count based on nLsmber of staff employed) during the year was as follows..
2022
2021
No.
No.
19.9
20.0
Postgraduate education & examinations
Conferences & academic activities
Professional standards
Clinical effectiveness
Advisory commillees
Communications & public relations
Wort(force
Education ntre
Inlernallonal development
15.4
13.4
63.9
60.2
The average number of full time equivalent employees dunng Ihe year was
58.8
8. Total expendlturg
(Current year)
Direct
Costs
Staff
Costs
Support
Costs
Total
2022
Total
2021
Trading activities & ed10n centre
Investsnent management fee
Postgraduate education & examinations
Pathology Portal
International development
Conferences & academic activities
Research
Professional standards
Clinical Effectivelless
Wotkforce
Communications & pLlIC engagement
Advisory commillees
777.538
41,682
541,110
124.248
16.346
8.350
116,626
508,022
1,402,186
41,682
2,202,566
160,987
359,539
415.176
946,270
23,557
1,750,826
138,871
360,670
354.816
3,462
269,543
259,300
313,OQO
1,096.090
413,749
981,890
36,739
179,417
258,415
679,566
163.776
148.411
5,116
20.257
120}
104,024
17,559
222,895
256,692
242,108
749,401
239,964
133,742
96,011
136,151
365,185
178,557
361,753
372,0
378,239
1,218,610
436,080
Total for the year ended 30 June 2020
1,656,210
3,284,147
2,409,421
7,349,778
5,930,154
8. Total expendlture
(Prior year)
Direct
Costs
Staff
Costs
Support
Coslg
Total
2021
Trading actNItEs & educalicln centre
Investment management fee
Poslgraduale education & examinations
Pathology Portal
Inlemational development
Conferences & academic aGlivilies
Research
Professional standards
Clinical Effectiveness
Wort(force
Communications & public engagement
Advisory committees
210,623
23,557
402,381
64,099
10,211
17,1011
3,462
3,713
10,248
888
128,893
55,626
65,194
670.453
946,270
23,557
1,750,826
138,871
360,670
354,816
3,462
269,543
259,300
313,000
1,096,090
413,749
908,043
74,772
213,985
246,775
440,402
1,474
115,142
155,596
176,257
203,570
687,045
228,188
110,234
72,795
108.542
280,152
129,935
Total for the year ended 30 June 2019
9,600
2,959.425
2,064,129
5,930,154
GoveTnarLce costs are contained within support costs and are not shown separately. They comprise the expenditure in
Te12tion to the trustee board of £12.437 (2021- £Nill. trustee recruitment costs of £Nil12021- £8.61n, legal costs of
£21,45312021- £20,832) and the auditors remuneration as detailed in note 9.
Page 23
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
9. Net Incoming re80urces for the year
2022
2021
This is staled after charging..
Depreciation
Audiloi's remuneration - external audit
Auditor's remuneration - payroll bureau serviGes
Trustee liability indemnity insufance
687,635
9.243
5,912
752
672,584
9,500
5,429
831
10. Ponslons
The College partlGipales in 2 pension schemes." the defined benefit Scheme, operated by SAUL Isuperannuation
Arrangements of the Univ8rsity of London} and the defined contribution 5¢heme, operated by Royal London.
SAUL scheme
The College participate5 in the Superannuation Arrangements of the University of London I'SAUL"). which is a centralised
defined beneffil scheme within the United Kingdom and was conlracled-out of the Second State Pension IprK)r to April 2016)
SAUL is an independently-managed pension scherne for the non-academic staff of over 50 colleges and institutions with
link5 to higher eduealion.
Pension benefits accNed within SAUL currently build up a Career Average Revalued Earnings I'CARE? basis.
The College is not expected lo be liable to SAUL fof any other current participating employerfs obligations under the Rules
of SAUL. but in the event of an insolven¢y of any participating employer within SAUL, an amount of any pension shortfall
(which cannot olhemise be recovered) in respect of that employer, may be spread across the remaining partipatIng
employers and reflected in the next actuarial valuation.
Funding Policy
SAUL'S slalulory funding ¢)bjective is to have sufficient and appropriate assets to meet the costs incurred by the Trustee in
paying SAUL'S benefits as they fall due {the"Technical Provisions )- The Trustee adopts assumptions which. taken as a
whole, are intended to be sufficiently prudent for pensions and benefits already in payment lo continue to be paid and for
the commitments which arise from Members. accrued pension righty to be mel.
The Technical Provisions assumptions include appropriate margins to allow for the possibility of events luming out worse
than expected. However, the funding method and assumptions do nol Complete remove the Tisk that the Technical
Provislons could be insufficient to provide benefits in the fvture.
A fomal actuarial valuation of SAUL is carned out every three years by a professionally qualified and independent actuary.
The last actuarial valuation was carrted out with an effective date of 31 March 2020. Informal reviews of SAUL'S position.
reflecting changes in market conditions, cash flciw information and new accrual of benefits, are carried out befv4een ft)mal
valuations.
The funding principles were agreed by the Trustee and Employers in June 2021 and are due to be reviewed again at
SAUL'S next fomal valuation in 2023.
At the 31 March 2020 valuation SAUL was 94% funded on its Technical Provisions basis. However,market movements
following the valuation dale were positive and the Trustees alld the Employers agreed to allow for FX)s1-valualion experEnce
up to 30 April 2021. As SAUL was in surplus on ils Technical Pruvisions basis at that date. no deficit contributions were
required. However, the The Trustee and Employers have agreed that the ongoing Employers, contributions will In¢3$e
from a rale of 16% of CARE salaries lo 190A of CARE salaries from 1 April 2022 and lo 21 % of CARE salaries from 1
January 2023.
Royal London schgm•
The College operates a defined contribution scheme for staff other than senior managers who joined the College after 1
April 2021. The assets of the scheme are held separately from those of the College in an independently administered fund
with Royal London. The pension cost charged represents the contributions payable under the scheme by the College to the
fund. The College has no liability under Ihe Scheme other than for payment of these c#)ntributICS.
Page 24
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
11. Allocatlon of co8t8
Support costs as per note 8 above. can broken down by activity. as follows..
Infomialion
technology
{Current yearl
Finance
Secretariat
Premises
Total
Postgraduate education & examinations
International development
Conferences & academic activities
Professional standards
Clinical effectiveness
Workforce
Communications & public engagement
Trading activities & education centre
Advisory committees
164.891
50,210
43,080
41,891
27.630
38.326
107,551
19,312
44,862
70,617
21.503
18,449
17,941
11.833
16.414
46,C60
8,270
19,213
409,212
81,452
77,778
65,057
50,709
73,312
188,846
476,359
105.W1
679,566
163,776
148,411
133,742
96,011
136,151
365,185
508,022
178,557
10,611
9,104
8,853
5,839
8,099
22,728
4,081
9,481
Total support costs year ended 30 June 2022
2,409.421
Included in information technology costs above, as allocated across the various departments, is an amount of £121,623
in retation lo non-recurrent IT costs.
Information
leGhnology
(Prior year)
Finance Secretarial
Premises
Total
Postgraduate education & examinations
International development
Conferences & academi¢ a¢tivities
Professional standards
Clinical effectiveness
Workforce
Communications & public engagement
Trading a¢tivilies & eduCatn centre
Advisory committees
166,005
54,509
46,183
45,477
29,996
41,607
136.046
20.959
48,702
99,942
32,796
28.139
27.363
18.048
25,034
70.250
12,614
29,303
25,943
8,513
148,512
40,656
33,516
30,291
20,066
35,403
55,620
633,606
44,323
440,402
136,474
115,142
110,234
72,795
108,S42
280,152
870,453
129,935
7,103
4,685
6,498
18,236
3,274
7,607
Totsl support costs year ended 30 June 2021
2,064,129
The basis of allocation of support costs is as follows..
Infomialion technology costs have been allocated on the basis of the number of computers used by department.
Finance SIS and secretariat costs have been allocated on the basis of the headcounl.
Pr8mises costs have been allocated on the basis of the usage of 00r areas.
Salary costs as per note 8 above can be further anatysed as follows..
Directty HR, Payroll
Attributable
&IT
{Current yearl
Finance
Secretariat
Premises
Total
Postgraduate education & examinations
Digital education project
International development
Conlerences & academic activit5
Professional standards
Clinical effectiveness
workf0e
Communications & public engageMt
Trading activities & education nITe
Advisory committees
Total salary costs year ended 30 June 2022
659,724
36,739
106,112
174,455
142,031
2LK),343
167,078
536,927
89,568
153,332
118,107
111,987
72,385
19.687
981.890
36,739
179,417
258,415
222,895
256,692
242,108
749,401
116,626
239,964
25,972
30,643
29,072
21,978
27,574
79,167
10,441
31,167
25.935
29,261
28,399
18,943
26,056
73,254
9,151
30.416
16,825
18,911
18,390
12,129
16,825
47,213
5,869
19,694
4,573
5,145
5.003
3,299
4,575
12,840
1.597
5.355
3,284,147
Pag8 25
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
11. Allocation of costs (continued)
Directly HR, Payroll
Atlribulable
&IT
{Prior year)
Finance
Secretariat
Premises
Total
Postg¥8duale edu¢alion & 8xaminatDn$
Digital education project
Intemalional devdopmenl
Conferences & academic activities
Professional standards
Clinical effectiveness
Workforce
Communi¢atr'on$ & public engagemer
Trading activities & education centre
Advisory committees
Tolal salary Costs year ended 30 June 2021
632,280
74,772
130,554
174,648
86,088
129,944
139,519
506,657
33,208
152,839
78,602
95,604
61,542
40,015
8,043
74,772
213,985
246,775
155,596
176,257
203,570
687,045
65,194
228,188
23.529
20.595
19,524
13,282
18.228
51.752
8.953
21,454
28,977
24,999
24,183
16.013
22,218
62,395
11,139
26,264
18,740
16,079
15,835
10,313
14,304
40,141
7,208
16,744
12.185
10.454
10,166
6,705
9.301
26,100
4,686
10,887
2,959,425
The basls of allo¢allon of salary costs is as follows=
Informatth technology costs have been allocated on the basis of the number of computers used by each departrnenl.
Finance costs. secretariat costs. premises cost8 and HR & payroll costs have been allocated on the ba8is of the
headcounl.
12. Taxation
As 8 registered charity the CoStege is exempt from corporats'on lax since all income is applied for charitable purp)ses.
13. Tanglbl• fix assgts
Consclidaled and College
Cornputer
Systems &
Softhare
Fixtures,
Flttings &
Equipm¢
Freehold
Property
Totsl
Cost or valuation
At 1 Juty 2021
Additions
Disposals
38,635.520
5.596
1.214.298
55,870
917,7 40.767.425
61,466
At 30 June 222
38,841.116
1,270,168
917.607 40.828.891
DeprElatIon
At 1 Juty 2(Y21
Provided In year
Disposals
832,593
372.824
938,386
159.290
592,861
155,521
2,363,840
687,835
At 30 June 2022
1.205,417
1,097,676
748.382
3,051,475
Nel tsk value at 30 June 2022
37,435,699
172,492
169.225
37,777.416
Nel tK)ok value at 30 June 2021
37,802,927
275,912
24.746
38,403,585
In addition lo the capilalised fixed assets held for the Charity's own use, the College also has a number of assets on tmsl
for retention in perpetuity as a permanent record of the College's history. These comprise a unique collection of paintings
depicting the College's 19 Presidents since its founding in 1962, togelher with a library collection and other artefacts whose
inlrin8ic value is asso bnd up with the College's history. These are Irreplaable originals lo which no reliable cost or value
can be attributed and accordingty these assets have not been capitalised in the financial statements.
P8g* 26
The Royal College of Pathologists
Notes to the Financial Statem8nts as at 30 June 2022
14. Investments
ConSolated
2022
2021
College
2022
2021
Market value at 1 Juty 2021
Additions at cost
Disposals al matkel value
Nel gain on revaluation
Market value at 30 June 2022
6.294.112 5,281,517 6,294.212 5,281,617
1,382,358
1,680,003
1,382,358
1.680,003
11.407,3571 {1,703.0301 {1,407,3571 11.703.fJ30)
11.035,9481 1,035.623 {1.035,9481 1,035,623
5.233.165 6,294,113
5,233,285
6.294.213
Historical cost at 30 June 2022
4.671.934
4.350,188 4,672,034
4,350,288
Investments at market value comprised-
Frx8d interest securities
Listed equty shares
Listed investment twsls and unit trusts
Cash held by inv&slmenl manager awarting reinveslmenl
Investment prope
Unlisted investments
206.989
233.948
280.594
2.592,860
3,915,142 2,764,894
132.328
4,299
698,112
698.112
206,989
233,948
280,594 2,592,860
3.915.142 2,764,894
132.328
4.299
698,112
e98,112
100
100
Market value as at 30 June 2022
5,233,165
6,294,113
5.233.265 6.294.213
Th8 investment propety is valued by reference to the market value of similar properties in the development, which, in the
opinirm of the Trustees, is the fair value at 30 June 2022.
Unlisted investments at cost comprise..
2022
2021
RCPth Trading Limited- 100 ordinary shares of £1 each
loo
100
100
100
The College owns 100% of the ordinary Sha eapital of RCPath Trading Limited, Company numb8r 4535296, which has
been consolidated as a subsidiary undertaking throughout. The registered address of the company is 6 Alie Street,
London E18QT.
Further detsils ol the investment poltcy and objectives are contained in the investment policy section of the report of
the Trustees.
15. Stocks
Consolidated and College
2022
2021
Memorabilia for resale
4,489
4,900
4,489
4.900
Page 27
The Royal Coll8ge of Pathologists
Notes to the Financial Statements as at 30 June 2022
16. Dobtor5
Consolidated
2022
2021
College
2022
2021
Trade debtors
Prepayments and accrued income
Other debtors
Amounts due from subsidiary undertakir
294,458
175,928
333,307
27,327
137,470
312,668
34.909
175,928
333,307
593,189
7,925
137,470
312.668
386,547
803.693
477,465
1,137,333
844,610
The amount duè frem thè subddLqry undertaking of £593,189 1$ dut after mor¢ than Or yoaf.
17. Cr8dltor8
Consolidated
2022
2021
College
2022
2021
Amounts falling due within one year
Deferred income {note 18)
Trade Creditors
other creditors
Taxation and social security
Accruals
Bank Loan
3,378,715 2,777,290
319,435
183,253
129.804
92.992
81,780
63,685
406,582
605.029
291,250
317,830
3,244,738
126,789
129.804
81.780
402,868
291,250
2.746,855
138,698
92,992
63,685
598,879
317,830
4,607,566 4.040,079
4,277,229
3.958,939
Amounts falling due after more than one year
Con$olhlated and College
Bank loan - amount due ben 2 and 5 years
Bank loan - amount due after 5 years
2022
2021
1,240.642
7,082.315
1,323.430
7,468,926
8,322,957
8,792,356
The loan is a ccqnmercial mortgage loan secured by a first legal charge over the land and building owned by the Cc41ege
al 6 Alie Street. Interest is charged al 1.5% above base rate.
18. Deferred Income
Consolidated
2022
2021
Colge
2022
2021
Balance al 1 July 2021
Amount lease¢Y lo incoming resources
Amount deferred in the year
2.777,290 3,129.527
2,746,855
3,129,527
12,765,730} 13,129.5271 12,746,855} 13,129,527)
3,367, 155 2,777,290
3,244,738
2,746,855
Balance as al 30 June 2022
3,378,715
2,777,290
3,244.738
2,746,855
Deferied income comprises income from subscriptions, trainee regislialion, examinations, GonferenGes and continuing
professional developmen( received in advance, that will form part of incoming resou[S during the following financial year.
The College was in receipt of £500.000 of statutory funding for the year12021- £198,570) by way of grants for specific
projects and, in addition, for the prior year the Coronavirus Job Retention Scheme. All conditions relating to these
grants have been met in full.
Pe 28
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
19. Movements In Funds
(Current yearl
8alance at
1 July 2021
Incoming
Resources
Outgoing
Resources
Translers
Gains and
Losses
Balare al
30 June 2022
Restricted lunds
Research Pool Fund
Oliver Memorial Fund
Bhagwan Singh Fund
Flynn Lecture & Bursary Fund
Kohn Memorial Fund
Developmental Pathology Fund
Medical Examiner Training Fund
E-leaming Project Fund
International Challenge Events Fund
Public Engagement Fund
Furness Prize Fund
Summer School Fund
William Tong Memorial Fund
Pathology Portal Fund
MTI Fund
Arise Project Fund
Galea PTize Fund
Undergraduale Pathology Fund
Covid Portal Fund
Ghana Project Fund
22.278
164.215
88.486
240,056
41,290
26.05D
24,617
50,271
22.721
2,530
359
20,529
2,688
602,560
50,271
57,682
5,003
37,028
22,289
121,978
62,912
165,65S
29,831
19.462
543
157
643
(6211
{42,1591
(25.7311
(75,0441
{11,4601
16,5901
51
26
12
124.668)
150,297}
22,733
2,531
159
35,040
2,689
941.899
50,297
51,391
5,006
37,047
40,000
{2001
13,511
1,000
500,326
26
30
1160.987}
16,321}
19
40,000
10,021
5,384
110,021)
1253,115)
1.458,634
1,000
1160.9841
1.610,919
Unrestncted Funds
Designated funds
Propety Fund
Cancer Reporknng Fund
EQA Fund
Premises Marf(eting Fund
60th Anniversary Fund
Examinations Development Fund
Technology Replament Fund
Major Repairs Fund
Corporate Membership Fund
General unrestricted fund
28,692,741
39,Ik86
50,000
37,594
10,000
100,000
400.000
100,000
7,416
7,596.098
128,753
28.821.494
31298
50,000
36,440
10,000
IDD,000
400,000
100,000
7,418
1874,Wl
6,787.507
11,035,948) 37.955.074
17,768)
11,154
7,283,867 {7,087.741} 1129,753)
7,849,251
{7,349.778}
Totsl Funds
38,491,549
The transfer from the designated prcpety fund is so as lo manlain the balance on the fund being equal lo the net book
value of the land and buildings s5 the capitsl outstanéing on the mortgage loan.
The transfer to the summer schools fund represents the College's share of the funding for this actimty to match that
made by other individual pathology associabons who jointly run this event.
Page 29
The Royal College of Pathologists
Notss to the Financial Statements as at 30 June 2022
19. Movements in Funds
{Prior perthl
Baknce at
1 Juty2020
Incoming
Resources
Outgoing
Resources
Transfers
Gains and
Losses
Balance at
30 June 2021
Restslcted funds
Research Pwl Fund
Oliver Memorial Fund
Bhagwan Singh Fund
Flynn Lecture Fund
Kohn Memorial Fund
Developmental Pathology Fund
Medical Examiner Training Fund
E-learning Prqecl Fund
Intemational Challenge Events Fund
Public Engagement Fund
Furness Prize Fund
Summer School Fund
William Tong Memorial Fund
Pathology Portal Fund
MTI Fund
Arise Project Fund
Galea Prvze Fund
UndergTaduate Pathology FurKJ
25,725
145,895
62,853
153.733
28.707
18.814
101,491
50.243
27.705
2.529
559
14,521
2,686
566,112
50,243
57,650
5,000
50,000
15
596
212
829
13,4621
115,621)
22.278
164,215
88,486
240.056
41,290
26,050
24,617
50,271
22,721
2,530
359
20,529
2.688
602.560
50,271
57,682
5.003
37,028
33,345
25,421
85,494
12,581
7,234
176.942}
28
16
15,0001
{2001
5,008
1,000
175,319
28
32
1138.8711
28
(13,0001
1,364,466
182,189
1253,0961
1,000
164,075
1.458.634
Unrestri¢t8d Funds
Designated Property Fund
Designated Caneer Reporting Fund
Designated EQA Fund
Designated Piemises MarkelNJ FurKI
601h Anniversary Fund
Examinations Devek)pmÈnt Fund
Technology Replacernent Fund
Major Repairs Fund
Corporate Membershlp Fund
28.729.321
46,649
so.000
38,194
136.580)
28.692,741
39,¢
50,000
37,594
10,000
100,000
400,000
100,000
7,416
{7.583)
16001
10,000
100,000
400,000
100,000
30,000
{22,5841
Generai unrestricted fund
6.424,037
6.551,224 15,646.2911 1604,420)
6.733,413 15,930,154)
871,548
7.596,098
Totsl Funds
36,652,667
1.035.623 38,491.549
20. Restricted and deslgnated funds
The Research Pool Fund was established in 1995 to promote research in pathology.
The Oliver Memorial Fund was oslablished to perp&luate the name of Percy Lane Oliver, by providing an annual nalional
award for servt¢e to blood transfusion, and for the furtherance of knowledge relating to the prineiples and praetices of
blood transfusion.
The Bhagwan Singh Fund was established in 1982 to sponsor occasional visits between the UK and Malaysia, to promote
Malaysian pathology.
The Flynn Lecture Fund was established in 1998 to fund an annual lecture in clinieal biochems81ry. Additionally, a nLtmber
of bursaries are awarded to trainees lo attend the sryentific meeting where the lecture is delivered. In the College's 60th
anniversary year a Flynn Lecture is being held in each n81ion of the UK.
The Kohn Memorial Fund was established in 1987 to fund an annual lecture mainly in clinical bio¢hemislry.
The Devek)pmental Pathology Fund was established in Juty 2004 as a grtt from the Developmental Pathology Soclety to fund
an occasional named 'Emety' leelurè in dIatriC pathology.
The Medical Examiner Training Fund was established by grant in aid from the Department of Heatth (Engkndl to support
the development of e-leaming materials and face to face training for medul examiners of the cause of death.
The E-leaming Project Fund was established to fund the provision of elèctronlc learning for pathology consuhanl8 and
trainees, and is supported by grant in aid from e-Leaming for Healthcare, part of Health Education England.
Pag& 30
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
20. Rèstricted and designated funds {contlnued}
The Path0kY Portal Fund was estsblished by grant in aid from Health Education England lo develop 8nd implement a
competence based molel of learning support on a digital platform for pathologywhich wou* include digitisation of
examinalions.
The Inlemational Challenge Events Fund was established to raise fvnds tor the College's intemab'onal devek)pmenl
projects.
The PublK Engagement fund was established byway of a prE8 awarded by The Royal Society to Dr Suzy Lishman for
her work on behalf of the COle on public engagement and is available forthe College's Publ engagement work.
Th8 Fumes8 Prize fijnd Wd8 estsblished in 2010 to fund an annual prize in sCi8nce ccxnmunicalion in relation to palhobgy.
The Summer Schod Fund was established to collect and adminisler the funds to run the annual patholo9y summer
schwl, which is fuNJed and run in association wrth a number of pathology specialist societies,
The William Tong Memorial Fund wa5 established by way of donations frcxn the fami and friends of the late William
Tong to provide an annual prize lo a trainee in vÉrology on the basis of a piece of work submitted as a poster.
The MTI Fund was established by grant in aid from the West London Canr Alliance to deliver training opportunities
across London for international medical graduates in histopathi)logy as part of the medicd training inilialive.
The Arise Project Fund was estsblished by Giant in Aid frorn the European Uni)n to fund the College's involvement in
a mulli-partner research project lo share and spread best practice in newborn screening, diagnosis and treatment of
SKkle Cell Disease, leading to improvements in overall disease outcome.
Tho undergraduate pathology fund was established lo create undergraduate and foundatNJn tsster events and materials to
5UPPOrt recruf(ment in pathology, to provide bursarie5 under the mlca1 eknlive heMe.
The Galea Prize Fund was established by way of gTft from Metabolic Support UK lo fund an annual prize to encourage
research into a therapy that will ameliorate and in future help find a cure for molabolic dwrders and inherited rare
eonditions.
The Covid Portal Fund was established to fund a researeh project to Interrogate the Covid post-mortèm portal to prowde
learning from the pandemtc which will be disseminated by way of18aning materials, webinars or stsentific papers.
The Ghana Project Fund was e8lablished by Grant in Aid from The Trop1 Heahh and Education Trust to produce 24
wèbinars lo support the new patholoJy ¢1cUla ofthe Facumy of Pathology of the College of Physicians of Ghana.
The designated propety fund was established following the disposal of the College's prewous functional property to
hold the funds that were required (excluding the amount lo be borrowed by way of mortgage loan) for the acquisition
and redevelopment of the Alie Street premises.
The designated cancer reporting fvnd was established to fund the College's Share of Ihe commitment to the International
CollaboTation on Cancer Reporting. whose aims are lo pursue global hamonisation of cancer dalasels for pathology
reporting. The ICCR has been incorporated as a not for profit organisalion and the College is a foundation member.
The designated EQA fund was established lo fund inilial expenditure on interpretive EQA and tsChnal EQA
monitoring systems.
The designated premises marketing fund was e5tabli¥hed for expenditure on the marketing of the facilities al Alie
Street that will generate revenue for the College in subsequent years.
The designated 60th anniversary fund was established lo fund actNitS associated with Ihe 60th anniversary of the
founding of the College, which wll be on 21st June 2022.
The designated examinations development fund was established lo fund the devel¢)pment of the digitisation of College
Èxaminations.
The designated te¢hnology replacement fvnd was established to fund the replacement of the Collège's central databa$e
system, which is an enterprise wde system incorporating membership. finance. exam5nations, training, CPD, academic
symposia, and a dynamic link that Integrates to the College website.
The designated mqor repairs fund was established to create a sinking fund for the Tepair and replament of major
pieces of plant and equipment wlhin the College's premises al AIK9 Street.
The esjnated corporate membership fund was established to fund the develcpmenl and expansion of the College's
corporatè membership scheme.
Page 31
The Royal College of Pathologists
Notes to the Financial Statements as at 30 June 2022
21. Analysis of group net assets between funds
{Current yearl - Consolldated
Tangible
fixed assets Investments
Net current
assets
Long term
liabilities
Totsl
Gèneral unrestricled
Designated
Restricted
341.716
37,435.700
4.836,767
1.609,024
443,905
1,214,521
6,787,507
(8,322,9S71 29.556,648
1.610,919
396,398
Net assets as at 30 June 2022
37,777.416
5.233,165
3,267,450
{8,322,9571 37,955,074
21. Analysls of group net assots between funds
(Current yearl - College
Tangible
rixed assets Investments
Net current
assets
Long term
Total
General unrestricted
Designated
ReStrted
341,716
37.435,700
4.836,867
2,028,507
443,905
1,214,521
7,207.090
18,322.957} 29,556.648
1,610,919
396,398
Net assets as at 30 June 2022
37,777,416
5,233,265
3,686,933
{8,322,95n 38,374,657
21. Analys1$ of group net asset8 between fund8
(Prlor yearl - Congolidated
Tangible
fixed assets Investments
Net current Long temi
assets
Total
General unreslricled
Designated
Restricted
600.658
37,802,927
5.736.776
1,258,684
426,246
901,297
7,596.098
18,792,3%1 29.436.817
1,458.634
557.337
Nel assets as at 30 June 2021
38,403.585
6,294,113
2,588,207
18,792,356) 38.491.549
21. Anatysis of group net assets betsveon funds
(Prior yearl - College
Tangible
fixed assets Investments
Net current
assets
Long lerm
liabilities
Total
General unrestricted
Designated
Restricted
600.658
37,802,927
5,736,876
1.701.957
426.246
901.297
8,039.491
18,792.3561 29.436,817
1,458,634
557.337
Nel assèts as at 30 June 2021
38,403,58S
6,294,213
3,029,500
18,7Q2.3%1 38.934,942
22. Prosentational curroncy
The presentational currency is Sterling.
23. Conting&nt asset
During the year the Collegé incurred non-recurrent IT costs. An Insurance clalm has been submltted. which, at the
balance Sheet dato has yet to be a¢cepled.
Page 32
The Royal College of Pathologists
Pathology.. the science behind the cure
Annual report
& accounts
2021-2022
## **Contents**
## Introduction
04 Welcome from the President 05 Message from the Registrar
## Our strategy & achievements
- 08 Our strategic vision and aims
- 10 Supporting pathologists and future pathologists throughout their careers 18 Improving patient care
- 24 Shaping the future of the profession 30 We are regional
- 34 We are international
## Celebrating 60 years of the College
- 40 Your College 41 Our Diamond Jubilee
## Introducing the College
The Royal College of Pathologists is a professional membership organisation with more than 13,000 fellows, affiliates and trainees worldwide. We are committed to setting and maintaining professional standards and promoting excellence in the teaching and practice of pathology, for the benefit of patients.
Our members include medically and veterinary qualified pathologists and clinical scientists in 17 different specialties, including histopathology, haematology, clinical biochemistry, medical microbiology and veterinary pathology.
## Our specialties and case studies
- 50 Our specialties
- 54 Implementing a newborn screening programme: our experience in Kaduna State, Nigeria 56 Improving blood matching for transfusions in patients with sickle cell disorder 58 Finding a novel cause of primary immunodeficiency
- 60 Combining dentistry and pathology to diagnose and treat oral cancer
- 62 Multiple myeloma: entering a new era of genetics 64 Tackling bird flu in the UK
- 66 Advances in the management of thrombotic thrombocytopenic purpura
The College supports pathologists at every stage of their careers. We set curricula, organise training, run examinations, publish clinical guidance and provide opportunities for continuing professional development.
We engage a wide range of stakeholders to improve awareness and understanding of pathology and the vital role it plays in everybody’s healthcare. Working with members, we run programmes to inspire the next generation to study science and join the profession.
## Our governance
70 Governance of the College 72 Financial report
**On the cover:** Students from the College's Diamond Jubilee Open Day take part in the Heart of Healthcare origami session.
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS** ANNUAL REPORT & ACCOUNTS
**SECTION 01** INTRODUCTION
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS SECTION 01** ANNUAL REPORT & ACCOUNTS INTRODUCTION
## Welcome from the President Professor Mike Osborn
This Annual Report is a celebration of pathology and pathologists. It highlights our collective mission in providing the best pathology service we can.
Welcome to the 2021–2022 Royal College of Pathologists' Annual Report. In this year’s report we highlight some of the many activities of the College over the last year. We also look forward to the future of the College and how we plan to develop our services to allow us to provide the very best pathology services we can for our patients.
2022 marks the 60th anniversary – the Diamond Jubilee – of our College. This is a fantastic landmark and it has provided us with the opportunity to look back and reflect on the amazing contribution pathologists and pathology have made to healthcare in the UK and worldwide since 21 June 1962 when the College was founded. As part of our Diamond Jubilee celebrations, this Annual Report will highlight our activities to showcase these achievements and the people who have been involved with them. We will also report on the wonderful events that have taken place over this year to celebrate this great milestone.
In 2021, we launched our new three-year strategy. Building on our previous strategies, this focuses on putting the needs of our members at the core of all our College functions and activities. Only by supporting and championing the needs of our members and those of pathology as a whole can we continually develop, refine and improve the quality of care we, and our colleagues in other healthcare specialties, provide to patients throughout the UK and worldwide.
This Annual Report is a celebration of pathology and pathologists. It highlights the College's values, aims and our collective mission to ensure patient safety by supporting the great work of our members in providing the best pathology service we can for all patients. I hope you find it interesting, engaging and informative.
The other core focus of our threeyear strategy is improving patient safety. Our activities as a College are centred on both members and patients – providing members with the tools and support they need to provide high-quality, dependable and safe healthcare for patients.
## Message from the Registrar Dr Lance Sandle
During 2021–2022, the College responded and adapted to the challenges created by the pandemic.
Although we are still in its slipstream, 2022 has seen a return to some pre-pandemic working practices, such as face-to-face meetings at Alie Street and in-person examinations. More of our interactions and meetings are now of a hybrid nature and this change in our working environment will undoubtedly become embedded practice. This is both owing to the flexibility provided, but also because of economic imperatives, with increased pressure on resources caused by the ongoing conflict in Ukraine and the consequences of the pandemic.
There have been events to raise awareness of the College within the wider community such as a concert at the Royal Liverpool Philharmonic, participation in the Welsh National Eisteddfod and a pet portrait competition, which served to highlight the role of our veterinary fellows.
It is essential that the College reflects its membership at all levels and progress has been made and is reported on within this report. However, there is still a long way to go and over the next year we will be working with members to help us identify and address inequalities. There has been ongoing reappraisal of the staffing structure to ensure that we have the staff needed to deliver on our commitments and mission as a College while managing finances at this difficult time.
Despite ongoing international health issues, geopolitical uncertainty and domestic industrial unrest, we have still been able to enjoy success stories. The College’s Diamond Jubilee has been celebrated with a variety of activities across all four nations of the UK, highlighting the value of pathology to the public.
Be reassured that thanks to the efforts of staff and officers the College will remain successful and relevant for the next 60 years.
Traditional events such as scientific meetings, alongside College endowed lectures, showcase the breadth of contribution to a wide range of subspecialties. Meanwhile, exercise-based activities (both real and virtual), including cycling, running and walking, have proved a popular way for members to celebrate our Jubilee and raise funds for worthy causes.
5
4
" We want to be a constant support for our members, whatever their specialty and whatever their stage of career. We’ll always speak up for their interests, to get policies in place that help them to help patients.” 02
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
## Our strategic vision and aims
Developing and supporting excellence in pathology for healthcare across the world.
## **Our mission**
Advance the science and practice of pathology.
Further public education in the field of pathology.
Promote study, research and innovation in pathology and disseminate results.
## **Our 2021–2024 strategy**
In 2021, we published our new threeyear strategy, which was developed with all of our members, and with patient care and safety at its core. It highlights the College's values, aims and our collective mission to shape the future of pathology.
## **Strategic aim 1**
- Support all members through the delivery of highquality member services
We’re committed to delivering member services that promote diversity and inclusion and support continued career development.
## **Strategic aim 2**
- Develop and maintain high standards of education, training and research across all pathology specialties
We’re committed to setting high standards for pathology education, training and research, to improve patient care and safety.
## **Strategic aim 3**
- Promote excellence and advance knowledge in pathology practice across all specialties
We work with members to improve the services they deliver to patients in disease prevention, diagnosis and treatment.
## **Strategic aim 4**
- Increase the College’s influence through a clear, coherent, professional voice
By communicating the central role that pathology plays in patient care, outcomes and safety, we’ll strengthen our position as an expert body, extending our influence and affecting national and international policy for the benefit of patients and pathologists.
## **Strategic aim 5**
- Resource the future development of the College
- We’ll make best use of the College’s resources and improve financial stability to achieve our strategic aims and charitable objectives.
9
8
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
## Supporting pathologists and future pathologists throughout their careers
We support our members through a range of initiatives and digital platforms that help drive their careers and pathology forward. Our continuing professional development accredited programme is always evolving to reflect changes in pathology education and practice. We’re committed to delivering inclusive member services and providing support and guidance around areas such as wellbeing and mental health. We are working with our members to further our work in these areas.
their ability to progress through their training programmes. Although there was a strong desire within pathology departments to reboot training as soon as possible, it was essential that there was a clear understanding of any issues this may involve.
## **Wellbeing and mental health**
**15**
The COVID-19 pandemic and successful the extra pressure and stress Certificates of experienced by all healthcare Eligibility for Specialist professionals brought wellbeing, Registration (CESR) burnout and mental health into recommended to the spotlight. Although these the General Medical have long been issues affecting Council our members, there has been a renewed opportunity to highlight to policymakers how the issues our members are facing can affect their physical and mental health. Providing exceptional patient care becomes **131** more difficult for a workforce not properly cared for themselves.
The survey results showed that wellbeing had been significantly affected, with trainees experiencing burnout and higher levels of stress. With workload increasing in response to the backlog of cases and tests, the College is acutely aware that this could be further exacerbated, with trainees leaving the specialty. We’ve been lobbying policymakers and NHS training bodies, highlighting the issues around training caused by the pandemic, but also reiterating that there were issues in pathology before COVID-19.
Certificates of Completion of Training (CCT) recommended to the General Medical Council
The College is committed to opening up conversations and providing support for our members at all stages of their career.
We’ll keep using the data gathered to highlight what support and resources pathology trainees need; for example, investment in digital pathology equipment, equality in access, and recognition that greater case exposure will be required for some trainees.
## **The need for responsive pathology training programmes**
The College’s Trainees’ Advisory Committee launched the COVID-19 impact trainee survey in summer 2021. This assessed the effect of the pandemic on trainees’ wellbeing and
## **Starting the conversation**
Our professional development blog series by Dr Chris Tiplady started in January 2020. It touches on subjects from stress, coaching and mentoring and burnout, to grief. The blogs offer advice and the opportunity for selfreflection. They’ve resonated strongly with our members and healthcare colleagues, particularly over the last year, being shared widely across social media. ‘The Empty Chair’ blog, which was viewed over 18,000 times, recognises the importance of unpaid carers and reflects on the COVID-19 pandemic, when empty chairs became a very common sight. We’ll continue to develop this series as part of our efforts to build a supportive culture for our members.
Members have been given the opportunity to share their experiences with each other in our evolving _Bulletin_ , which now covers a wider collection of topics. Our April issue featured articles on mental health and wellbeing, discussing the importance of reflecting on our mental health and the need for better for support for healthcare professionals.
## **Supporting new consultants and trainees**
With the NHS under increasing pressure, we recognise the impact this has on pathologists and all healthcare workers. Working in a system under extreme pressure is likely to increase burnout and decrease retention. For those taking on new roles, the pressure can be even greater as they face new challenges and responsibilities.
To support recently appointed consultants or those shortly taking up a consultant post, we launched
We've been lobbying policymakers and NHS training bodies, highlighting the issues around training caused by the pandemic, but also reiterating that there were issues in pathology before COVID-19."
a new event in April 2022 – New Consultants’ Day. The event was open to new consultants of all **132** pathology specialties, and both medical consultants and consultant new specialty clinical scientists. Attendees heard registrars registered the experiences of others who’d with the College already made the transition from trainee to consultant and could offer tips and advice. They spoke about the reality of the first few weeks and months in a new consultant post, as well as specific areas such as revalidation and appraisal, handling complaints, and obtaining resources.
Our annual New Trainee Welcome Day introduces new trainee pathologists to the College and provides them with a clearer picture of our role, pathology training programmes and examinations, and what support is on offer. We had more than 145 trainees join us for our 2021 event.
The College Alongside presentations covering is committed general pathology information, to opening up there were also tailored specialty breakout sessions to delve deeper conversations into new curricula and assessment and providing and examination requirements for each specialty. To increase support for interaction during this virtual event, our members we used an audience interaction at all stages of platform. Trainees could submit their questions as well as upvote their career." the questions of other participants.
10
11
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS** ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
All the sessions were recorded and these resources alongside the Q&As are available on our website.
## **191**
events approved **Equality, diversity and inclusion** for continuing professional Equality, diversity and inclusion development
Equality, diversity and inclusion (EDI) are central to the work of our trustees, Council and leadership team. Over the past year we’ve made good progress in establishing the framework to support improvements in these areas. Our EDI Network, established by Esther Youd, former Assistant Registrar, brings together those with expertise, interest and lived experience in EDI matters to discuss key areas and emerging issues.
The Network has delivered some great work so far. For example, in April 2022 some of the members held a panel discussion on disability adjustments in pathology. It was a fantastic opportunity to celebrate how inclusive pathology is and the value diversity brings.
Our 2021–2022 action plan sets out how we’re addressing issues relating to access, fairness and openness. It also outlines the work we’ll do to better support people in assessing impact, ensuring appropriate language is used, and making reasonable adjustments. There are also a range of actions we’ll take to ensure inclusivity and promote and support diversity.
**Identifying and addressing barriers to engagement** It’s important that we build the data to help us understand our
members’ characteristics and any barriers they face in engaging with us. Collecting this information, along with other data, will help us identify and address inequalities, improve diversity and assure inclusion.
Working with members of the EDI Network and staff at the College, we’ve now developed two surveys. The first of these seeks to better understand our members and asks for information relating to: protected characteristics; socioeconomic indicators; work patterns and caring responsibilities; and work settings and plans.
This survey is voluntary, and all questions will have a ‘prefer not to say’ option, but the data we collect has the power to drive significant improvements that will benefit all our members. The second survey seeks feedback on any barriers members face in engaging with the College and will be used to help remove these barriers wherever possible.
## **Continuing professional development**
A key commitment we’ve made to our members is to provide excellent continuing professional development (CPD) support services. In response to the demands placed on our members by the pandemic, we again extended the deadline for CPD returns giving participating members an extra three months to submit. This gave them some much-needed breathing space.
The pandemic changed the CPD landscape and it’s likely that this change will be permanent. We see this as an opportunity to support increased accessibility to a more varied programme of
## CPD activities. As our members
navigate change, we’ve offered regular tips and advice via our social media channels on various aspects of CPD, including how to participate in various activities. We’ve developed our CPD programme to cover volunteering activities, with College accessors sitting on Advisory Appointment Committees and job description reviewers now able to obtain CPD points. We’ll also extend our guidance on CPD to cover reflective learning, selfaccreditation and volunteering.
We want to ensure that our CPD portfolio meets our members’ needs and we’re continuously looking for ways to further improve this service. We recently asked CPD participants for their views on topics such as our online portfolio and retention times for supporting information uploaded when entering activities. It was encouraging that 77% of participants stated that they were happy with the current online CPD portfolio, but we know there’s more we can offer members to support their growth and it’s an area we’ll work on as part of our three-year strategy.
"The pandemic changed the professional development landscape… We see this as an opportunity to increase accessibility to a more varied programme of activities for our members."
## **Access to learning**
We’re always evaluating our member services, looking for ways to improve user experience and consistent access to learning, whether by bringing in new functionality or developing new technologies and platforms.
Our Equality, diversity and inclusion (EDI) network brings together those with expertise, interest and lived experience in EDI matters to discuss key areas and emerging issues.”
## **The new LEPT system**
## **680**
In September 2021, a new Learning Environment for Pathology Trainees **680** (LEPT) system was launched, initially for trainees who started Integrated trainees used both Cellular Pathology Training (ICPT) LEPT systems to and Chemical Pathology training create Annual Review from August 2021. The new platform of Competence was developed to support changes Progression (ARCPs) to curricula published in 2021 and is up to June 2022 the culmination of a two-year project. It offers more defined functionality and a user-friendly experience.
**9,197**
Brand new functionality embedded in the new LEPT system includes the Annual Review of Competence Progression (ARCP) form, which workplace-based deanery and Local Education assesments were Training Boards (LETBs) staff are used in those ARCPs able to initiate for the ARCP panel meetings. This allows trainees’ ePortfolios to be automatically populated with their ARCP outcomes, as members of the panel meetings will be able to complete the forms directly on the LEPT system.
Workplace-based assessments in the form of supervised learning events (SLEs) are also embedded.
13
12
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS** ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
Members of the Pathology Portal Editorial Board have worked tirelessly in loading a range of learning materials and teaching cases to the Portal covering areas such as allergy, blood transfusion, cellular pathology, clinical biochemistry, genetics, haematology, histocompatibility and immunogenetics, immunology, infection, metabolic medicine, reproductive science and toxicology. Materials and teaching cases for these and other specialties will be loaded on a continuous basis as the Portal evolves.
The SLEs are strictly formative assessments, aimed at reinforcing learning. Their primary role is to give feedback on performance as they offer the opportunity to monitor progress continuously.
## **The Pathology Portal**
The Pathology Portal officially launched in August 2022. An innovative adaptive learning platform designed to support trainees and practicing pathologists in digital learning, it has been in development since 2019 in collaboration with Health Education England (HEE) (it was previously known as Digital Now). It is hosted within the HEE Learning Hub and will be accessible via the College’s website through a single sign-on process as part of ongoing development work.
## **Celebrating pathology**
## **RCPath Achievement Awards**
The College’s annual Achievement Awards were launched in 2019 and celebrate excellence in pathology practice. They promote high standards in pathology education, training and research to deliver the best patient care.
We held three virtual bite-size sessions during autumn 2021 to demonstrate the new functionality to trainees and provide tips for using the new system. The old LEPT system will be phased out during the latter part of 2023 as all trainees, except for those in their final year of training, will effectively be transferred to the new system together with their training items; this process started in spring 2022. This also applies to Certificate of Eligibility for Specialist Registration (CESR) doctors using the old LEPT system. We’ll continue to support trainees during their transfer to the new system.
Nominations were invited for teams and individuals of all professional backgrounds and disciplines. The winners were presented with their awards virtually as part of the College Council meeting on Thursday 18 November 2021 with College President Professor Mike Osborn congratulating them.
Using technology to enhance learning, the Portal incorporates the ability to host a range of learning materials, including virtual microscopy whole slide imaging, to enable pathology tissue samples to be annotated and viewed as part of learning sets.
## **Patient safety**
Dr Laura Green won this award for her vision and expertise in integrating research into clinical service, driving changes that optimise NHS resources, reduce national variability and improve the standard of care for patients.
The Pathology Portal is a fantastic, innovative training and educational resource that trainees and practicing pathologists will be able to access throughout their career.”
The Portal supports not only digital morphological learning, but also clinical and macroscopic learning. It includes the upload of material already scanned as part of previous deanery/LETB projects, to reduce duplication and provide broader access.
## **Innovation in pathology practice**
## **4,254**
Dr Maria O’Donovan won this award as co-inventor of Cytosponge, which aids the early detection of Barrett’s oesophagus, dysplasia and oesophageal cancers.
continuing professional development returns processed
## **Contribution to education**
Professor Shivayogi Bhusnurmath was recognised for his contribution to education. Professor Bhusnurmath has been actively involved in enhancing pathology education for medical undergraduates and postgraduate trainees around the world for over 45 years.
The RCPath Achievement Award winners exemplify the best of pathology practice through their work in furthering pathology education, improving patient safety and the innovation of new diagnostics and treatments – all for the benefit of patients. To achieve this throughout a global pandemic is truly inspiring.”
**Professor Mike Osborn President**
**Professor Mike Osborn President**
15
14
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** 2022 ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** 2022 ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
## **Contribution to specialty**
Dr Benjamin Brown was recognised for his contribution to medical microbiology. This included the development of the dried blood spot (DBS) testing service in Manchester, providing outreach training on DBS testing and supporting Public Health England’s response to the Ebola outbreak through his work in Sierra Leone.
Lise Estcourt, Dave Roberts, Sheila MacLennan and Heli Harvala were also acknowledged in this category for their research during the pandemic, which shaped the use of antibody therapy in the treatment of COVID-19.
## **Trainee research medals**
The College’s research medals are awarded for outstanding research work undertaken by trainees.
## **Gold medal**
## **William Hamilton**
Medical Microbiology (dual training with Infectious Diseases)
William won the gold medal with a paper on the use of rapid SARSCoV-2 sequencing and detailed epidemiological analysis to investigate healthcare-associated SARS-CoV-2 infections and inform infection control measures.
**Silver medals Lyn Ferguson** Chemical Pathology and Metabolic Medicine
## **Mark Ponsford**
Clinical Immunology
**Meng Wang** Haematology
**Caroline Young** Cellular Pathology
## **Sheila Lumley**
Infectious Diseases and Microbiology
**Muge Cevik** Infectious Diseases and Medical Virology
**Hugh Platt Foundation Essay Prize – Maeve McLaughlin** The winner for 2021, Maeve McLaughlin, discussed testing strategies for managing COVID-19, exploring the utility of the different tests available, the benefits of sewage analysis and highlighting the issues around the rapid emergence of private antigen tests.
Maeve is in her second year of training at the Severn Foundation School. Here's what she had to say about winning the competition.
"I am delighted, I really enjoyed learning about the subject and found it extremely relevant in the current climate."
**Paola Domizio Undergraduate Essay Prize – Rebecca Sarsam**
Medical, biological science and veterinary undergraduates wrote about the role of pathology in managing COVID-19. Rebecca’s essay highlighted the vital work of virologists in genome sequencing and the production of diagnostic tests, as well as the role of immunologists in the development of vaccines. Rebecca is studying medicine at King’s College London and currently undertaking an intercalated MSc in Immunology of Infectious Diseases at the London School of Hygiene and Tropical Medicine.
"I feel honoured and surprised to be selected as the winner of the Furness Prize. I am a strong believer in collaborative work, both in medicine and in science, and effective and efficient communication is key to achieving this. [My] passion has been to facilitate communication among budding haematologists to enable the brilliant research and audit projects performed at local level to be upscaled nationally."
"…the competition was a good way to practice essay-writing skills and explore areas of pathology that were only touched upon in my medical course, such as the roles of virologists and immunologists."
**Furness Prize for Science Communication – Dr Phillip (Pip) Nicolson** The Furness Prize for Science Communication
## **Key achievements**
celebrates and recognises trainees and undergraduates who have undertaken science communication activities to inspire awareness and understanding of pathology in others. This year’s winner was Dr Pip Nicolson, a Clinical Lecturer and Registrar in Haematology. Pip cofounded and chairs HaemSTAR – a network facilitating communication and promoting research among haematology trainees.
- Launching the Pathology Portal – an adaptive learning platform hosting resources and materials that will support trainees and practicing pathologists.
- Launching a new LEPT (Learning Environment for Pathology Trainees) platform to support changes implemented in the development of new curricula.
- Celebrating and supporting research and excellent pathology practice through our awards and competition programme.
16
17
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS** ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
## Improving patient care
Patient care and safety drives our work for excellence and innovation in pathology. We work directly with our members, kindred organisations and healthcare stakeholders to promote a strong safety culture within pathology. We’re driving changes to ensure a consistent and standardised quality assurance framework, developing high-quality resources and audits to raise international standards. This requires investment to achieve, and we’re advocating for the funding needed to keep delivering the best possible services to patients.
(EQA). Our aim is to work with stakeholders to support the development of a robust systems governance and assurance framework for EQA for laboratories in the UK. We’ve made progress, producing policies and standard operating procedures within the EQA improvement programme. These will help to identify and manage poor practice. They clearly set out the steps for escalation between EQA providers, National Quality Assurance Advisory Panels (NQAAPs) and the Quality Assurance in Pathology Committee.
## **Supporting service improvement 601**
## **Patient safety**
people attended our first three guideline implementation webinars
To mark World Patient Safety Day on 17 September 2021, our Professional Standards and Clinical Effectiveness teams launched Patient Safety Awareness Week, running from 17 to 23 September. The week encourages participation in patient safety activities and discussions in the workplace, and raises awareness of how we can support our members to improve safety in their workplaces.
## **6**
NICE-accredited guidelines were published
During the week we shared new resources on our website, including an infographic highlighting how highquality laboratory medicine underpins patient safety, and relaunched resources from previous patient safety campaigns. The resources are available all year round for members and we publish new patient safety bulletins every month to encourage shared learning and help create a strong safety culture.
## **Our role in external consultations**
This year the College has responded to external consultations from a wide range of organisations, agencies and societies, providing invaluable input to improve patient care and safety. We’ve had direct involvement in the National Institute for Health and Care Excellence (NICE) objectives and work programme and represented the professional interests of our members by contributing expert advice. Our Specialty Advisory Committees (SACs) are integral to this process, providing us with evidence and advice.
## **Improving external quality assurance**
We’re leading a review of the oversight and governance of technical external quality assurance
Our members helped us to successfully highlight pressures on NHS teams. We worked alongside other medical royal colleges and the Academy of Medical Royal Colleges to raise awareness of current workforce shortages. And we’re pushing for an honest conversation about the future of NHS healthcare with policymakers. We want to ensure that the expectations of government, staff and patients are realistic and there are adequate resources to meet targets.
## We contributed to the NHS
England and NHS Improvement consultation to support best practice around blood test requesting. The intention of this consultation was to both provide support during the current shortage of blood testing equipment, and to support recovery.
## **Setting standards**
## **Consistency through collaboration**
The pandemic shone a spotlight on the essential role of infection services in healthcare and highlighted disparity in the provision of infection services. Infection services are configured in a way that means there are differing amounts of infection expertise in different trusts and hospitals. As demand on these services continues to rise, so will the challenges, particularly around workforce. A one size fits all infection service provision is not appropriate, but standards are needed to ensure parity. Although standards exist for diagnostic laboratories and some aspects of patient care, to date, there hasn't been a single set of standards looking at the requirements of an infection service.
In collaboration with the British
## **92**
Infection Association and the Royal College of Physicians, we created a **92** single set of standards for delivering infection services. These draw on NICE and 8 external published guidance and evidence consultations were where they exist as well as extensive responded to experience in delivering infection services in hospitals across the NHS. They incorporate laboratory and clinical practice standards, and allow for flexibility, acknowledging the disparity in the provision of infection expertise within the NHS.
Members in infection specialties contributed to these standards through our consultation process and the College’s Medical Microbiology/Medical Virology SAC approved the final version for publication. The standards represent a baseline for infection services to benchmark themselves against and to provide an indication of the resource needed to provide a high-quality service.
## **Quality improvement**
Our NICE-accredited clinical guideline programme currently consists of cancer datasets, tissue pathways, autopsy guidelines and cross-specialty guidelines. We’re always expanding to cover different aspects of cellular pathology and are working to increase the number of guidelines we produce in other specialties. Over the last year we’ve been working to improve our guideline processes.
We're pushing for an honest conversation about the future of NHS healthcare with policymakers. We want to ensure the expectations... are realistic and there are adequate resources.”
19
18
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
We’re also building relationships with key organisations to share resources that will aid the development of our cancer datasets and tissue pathways. As a result, we’ve
formalised an agreement with the International Collaboration on Cancer Reporting (ICCR) and International Agency for Research on Cancer (IARC) that will benefit the development of UK and international standards in pathology reporting of cancer.
Clinical audits play a vital role in quality improvement in pathology. Our clinical audit templates ensure audit activities are conducted efficiently with maximum benefit to patient care while helping pathologists to meet the requirement of revalidation. These templates are published alongside our clinical guidelines to support guideline implementation. They also assist in promoting participation in work-based learning. The audit **7** certification scheme provides educational value to our members, patient safety bulletins fostering high-quality audit projects were published that are selected for publication, and helping pathologists with accreditation schemes such as UKAS.
## **18**
We're building relationships with key organisations that will... benefit the development of UK and international standards in pathology reporting of cancer."
audit templates were published
## **A sustainable workforce**
Our members work as part of an underfunded and under-resourced workforce. This hugely affects their working lives and the quality of care they can deliver to patients. Significant issues around workforce in pathology remain, and we continue to dedicate resources to advocate for a properly resourced, supported and sustainable pathology.
Member input into our workforce surveys is also vital in providing us with the evidence we need to lobby for changes.
## **Workforce reporting and planning**
The College’s Workforce team work in partnership with our SACs to analyse data from our workforce surveys. The analysis helps us to understand where current pressures and shortages exist, disparities between roles and locations, and what’s needed for the future to meet increasing demands for pathology services.
In July 2021, we published our cytopathology workforce report, which focused on diagnostic cytopathology outside the cervical screening programme. The report highlighted that 83.6% of pathologists reporting on cytopathology samples are general cellular pathologists rather than specialised cytopathologists – only 5.5% of the pathologists who responded identified themselves as cytopathologists. Given the retirement plans of the cellular pathologists who responded, there will be a gap in cytopathology reporting unless trainee pathologists and consultant
pathologists are encouraged to
report cytopathology samples. With around 25% of biomedical scientists planning to sit high-level qualifications in cytopathology, this will help fill staffing and service gaps. We’re working closely with the Institute of Biomedical Science to ensure that future cytopathology staffing models factor this in. There needs to be sufficient material for training, education and maintaining competence for all staff involved in cytopathology service provision.
Our veterinary pathology workforce report was published in summer 2022, focusing on the issues and barriers to recruitment in the UK. Our survey results highlighted difficulties in recruiting veterinary pathologists, with institutions having to go through multiple rounds of recruitment.
As part of our recommendations, we’re looking at how we can improve visibility of veterinary pathology among school students, undergraduates and trainees, and how we can increase access to and funding and support for training. We need to ensure there are the right numbers of trainees to meet demand. An action plan has been published and work is underway.
We launched neuropathology, virology and histopathology surveys and are currently analysing the data. We’ll be publishing reports for these specialties over the next year.
We want to ensure members can use our workforce data to understand what’s happening in their specialty and region. We have expanded access to workforce data on our website to provide a clearer and more up-to-date picture of the current pathology workforce.
Significant issues around workforce in pathology remain and we continue to dedicate resources to advocate for a properly resourced, supported and sustainable pathology.”
## **Informing and lobbying**
**26**
We continue to raise the issue of workforce at every opportunity with **26** government and policymakers. Our message is clear – we need the audits were right number of correctly trained, submitted to the skilled staff in the right place at the audit certification right time to provide the excellent scheme for evaluation healthcare our patients need.
Our workforce data has been used in responses to consultations by various Health and Social Care **349** committees. We also use the data to engage kindred organisations, job descriptions associated bodies and charities to were reviewed widen the reach of our voice and and approved to bring a patient-focused element to the issues we’re raising.
## **349**
We were pleased to see the influential House of Commons Public Accounts Committee report on NHS backlogs and waiting times in England feature College evidence highlighting pre-pandemic pathology workforce shortages. We welcomed the committee’s recommendations for an assessment of the number of staff that will be available to deal with the backlog and how staff working under intense and consistent pressure will be supported.
The Health and Social Care Committee expert panel on cancer services used much of our evidence on cancer services and workforce in their evaluation report. Highlighted areas included concerns that certain
21
20
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** 2022 ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
## **222**
College assessors attended advisory appointment committees in England, Wales and Northern Ireland
specialties don’t have enough staff in post to meet patient demand and that there have been workforce shortages for some time. The evaluation also reflected our concerns about how the new Cancer Diagnostic Centres across England would be staffed, and how the capacity of the workforce would expand to match the investment in diagnostic pathways.
## **Looking forward: workforce intelligence review**
This last year has seen great success with how our workforce data has been used as evidence to promote investment in pathology. We want to reach further. To this end, we are evaluating and remodelling our approach to the collection, analysis and reporting of workforce data. This is a significant project that will overhaul current processes. We will use the data to monitor workforce numbers, identify trends and issues, and highlight gaps in the pathology workforce to lobby for increased training places and resources for pathologists.
We welcomed the commitment in the Queen’s Speech of £2.3 billion for diagnostics with plans for over 100 Community Diagnostic Centres over three years. We’ve also highlighted that the pathology workforce will need to be expanded to manage increased investigative tests from the new centres.
Over time, these reports will benchmark how the workforce situation is evolving, identify whether specific issues are being adequately addressed, and provide robust data for internal and external College use. Information and data can be extracted to produce evidencebased briefings for decision-makers and influencers and assist them in advocating for the needs of pathology and pathologists and, ultimately, safe patient care.
The Health and Social Care Committee report on cancer services used our evidence on the shortage of pathologists. Now more than ever, it’s vital that services are sufficiently funded and supported to tackle the diagnostic backlog, particularly in cancer services.
We continue to raise the issue of workforce at every opportunity with government and policymakers. Our message is clear – we need the right number of correctly trained, skilled staff in the right place at the right time to provide the excellent healthcare our patients need.”
**Image:** College Registrar, Dr Lance Sandle, introducing the Dacie–Wilkson lecture at the 62nd Annual Scientific Meeting of the British Society for Haematology. Reproduced with permission from the British Society for Haematology, 2022.
## **Key achievements**
- Inclusion of our workforce data that highlighted pathology workforce shortages in the House of Commons and Health and Social Care Committee reports.
- Delivering Patient Safety Awareness Week to encourage shared learning around patient safety and a strong safety culture.
- Creating policies and standard operating procedures within the EQA improvement programme to provide the consistency and standardisation required to identify and manage poor practice.
- Securing a memorandum of understanding with the International Collaboration on Cancer Reporting (ICCR) and International Agency for Research on Cancer (IARC) that will benefit the development of UK and international standards in pathology reporting of cancer.
23
22
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** 2022 ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
## Shaping the future of the profession
Together with our members, we’re an influential collective voice for pathology. We can make sure governments, health stakeholders, the media and the public understand the expertise and vital role of the pathology workforce. This year, as ever, we’ve been very active in raising issues that affect the day-to-day lives of our members. Using data-driven evidence we continue to highlight workforce shortages and the impact those can have on patients. And we’ll keep calling for the resources needed now and in the future.
Professor Mike Osborn has been taking this message directly to parliamentarians and stakeholders. He met Jeremy Hunt MP, Chair of the Health and Social Care Select Committee, to give a pathology perspective on the workforce issues in healthcare. They discussed how a lack of resources and staff were becoming even more significant and were at risk of derailing any expansion of services that the government or stakeholders might want.
## **Influence and engagement**
## **Investment in pathology**
The COVID-19 pandemic has moved onto the next phase – recovery while living with the virus. However, one of the biggest issues in healthcare now is the backlog the pandemic has caused. Although most media coverage about the backlog has focused on cancer treatment, it is affecting all areas of healthcare and all our pathology specialties.
Similarly, Professor Osborn met Feryal Clark MP, Shadow Minister (Health and Social Care), and his local MP Ellie Reeves to discuss pathology issues directly affecting patient care, for example workforce and the impact of COVID-19. We’ll continue to work with MPs to raise issues that are important to our members.
There are various projections as to how long the NHS will be dealing with this backlog but, to make headway, the NHS needs to be adequately resourced and funded. The NHS Recovery plan was launched in February 2022 to tackle the elective care backlog over the next three years. In our response, we highlighted the role of pathologists in tackling the diagnostic backlog.
Other significant pandemic-related issues affecting pathologists include the training of junior doctors, laboratory staff and other colleagues. There were substantial workforce issues in pathology before the pandemic, as well as issues around technology, such as poor-quality IT and LIMS provision. These issues
Our message was clear on this – without targeted investment in pathology services, it will be impossible to achieve this target. The pathology workforce is key to reducing the backlog and crucial to disease prevention and infection control.
have not gone away and have only been intensified by COVID-19 and the associated backlog.
We’ve been working in all four nations to highlight these issues to policymakers and the relevant NHS, training and other bodies. We want all pathology specialties to have the resources they need to provide the highest possible quality healthcare to our patients.
We highlighted not just funding and training needs, but that future plans must not lead to fragmented pathology services. We’re raising the profile of pathology and will continue to do so.
## **Genomics**
Genomics has the potential to radically redefine diagnostics and healthcare. There is hope it will improve cancer survival statistics, as well as service access, equity and efficiency. College members are the driving force in harnessing the opportunities of genomics medicine for faster, accurate diagnosis and tailored treatment for people with cancer, and with inherited diseases.
However, there is no planned resource provision for the significantly increased workload that the Genomic Medicine Service will create for pathology, which will grow over time. Unless this is addressed there will be issues in providing the quality and level of service desired.
The College’s Working Group on Cancer Services, and the Cellular Pathology Genomics Focus Group, carried out a survey on genomic and molecular testing, and its effect on members’ workloads. The College also wanted a deeper understanding of how testing is implemented and can be improved, as well as overall
service delivery and patient care.
The results of the survey have informed discussions about the resourcing and structure of pathology laboratories as genomic and molecular testing is rolled out. We’ll continue to use the results to engage politicians and key organisations, making the case to government for sustained support for the pathology workforce across the UK.
Many College recommendations – such as genomic tests being approved for access via a registered health professional, and support for NHS professionals encountering patients who have used genetic tests – were included in a report from the House of Commons Science and Technology Committee on regulations for directto-consumer genetic testing. This followed a consultation where the College provided evidence with the Royal College of Physicians. Our evidence has also been published on the committee’s website.
Our message was clear on this – without targeted investment in pathology services, it will be impossible to achieve this target. The pathology workforce is key to reducing the backlog and crucial to disease prevention and infection control.”
25
24
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** 2022 ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
Ensuring the roles of pathology and pathologists are recognised is a priority and we have successfully moved from having almost no voice in genomics to representation on most of the significant committees involved in the roll-out of the Genomic Medicine Service.”
It’s a priority for us that the roles of pathology and pathologists are recognised. We’ve successfully made a voice for ourselves in genomics, with representation on most of the significant committees involved in the roll-out of the Genomic Medicine Service.
Professor Mike Osborn will co-Chair the ‘Task and Finish’ group along with Dame Sue Hill, Chief Scientific Officer for England. The group will lead the roll-out in England and our presence will allow pathologists to help steer developments and push for the resources needed. Professor Osborn also attended an influential roundtable discussion on tumour agnostic policy and associated genomic issues, hosted by the PHG Foundation. It highlighted issues to policymakers and stakeholders to help improve patient care.
## **Our work with All-Party Parliamentary Groups**
Dr Srinivas Annavarapu, Chair of the College’s Prenatal, Perinatal and Paediatric SAC, attended a meeting of the All-Party Parliamentary Group (APPG) on Baby Loss, which was held jointly with the APPG on Maternity. The College recommendations were well received by the panellists, especially the issues relating to the acute national shortage of the perinatal and paediatric pathology workforce.
Following this, Dr Annavarapu was invited to present spoken evidence to a meeting of the APPG on the staffing crisis in maternity services, to give the perspective of pathologists.
College Fellows attended the launch of a joint report from the APPGs on Blood Cancer and Stem Cell Transplantation and Cellular Therapies. The report looks at the impact of the COVID-19 pandemic on blood cancer services. We submitted evidence to this crucial inquiry, which investigated how the diagnosis and management of blood cancer have changed as a result of the pandemic, and what measures are needed for services to recover.
The College and the Transfusion Medicine SAC responded to the APPG on Sickle Cell and Thalassaemia report ‘No One’s Listening’ following their inquiry into avoidable deaths and failures of care for sickle cell patients. We endorsed the recommendations and welcomed the call for urgent action to ensure sickle cell patients receive care at a standard to which they are entitled.
We responded to the APPG for Allergy and the National Allergy Strategy Group report – 'Meeting the Challenges of the National Allergy Crisis'. We welcome the call for urgent improvement in UK allergy services, and support workforce expansion, but this shouldn’t come at the expense of clinical immunology and laboratory immunology services, which also require support and expansion. Following this we met Carla Jones, CEO of Allergy UK, who is keen to work more closely with us in the future. We hope to work collaboratively with the National Allergy Strategy Group and will be including them in one of the Immunology SAC meetings.
## **The importance of visibility**
We want to see improved recruitment in pathology, and we want to reduce the growing recruitment gap. We’ve been campaigning for greater investment in training to increase training posts in pathology, help attract trainees and ensure protected training time for those involved in training. We also have a programme of events that increase the visibility of pathology among school students, undergraduates and foundation doctors, and promote pathology as a career choice.
## **National Pathology Week**
National Pathology Week is our hugely successful annual celebration of pathology. With the 2022 event moving to June to coincide with our 60th anniversary, we’ve held two National Pathology Weeks within the last eight months. Our Public Engagement team, volunteers and members were integral to the success of both these events.
Our 2021 event had the theme ‘All Together Now’ inspiring a diverse range of events and activities. We invited our members to highlight how teamwork and collaboration help them to deliver the incredible work they do in our healthcare system, and how the 17 pathology specialties work together to diagnose, prevent and treat diseases.
The College-led programme included an RCPath Book Club, medical ethics workshops for medical students in collaboration with the Social Mobility Foundation, a veterinary pathology workshop for secondary school students with the Royal Veterinary College, a
webinar with Malcolm Robinson – the founder of inspirational charity Harvey’s Gang, and virtual pub quizzes for undergraduates studying medicine, biomedical science and veterinary medicine.
Our virtual pathology careers talks focused on secondary school students. More than 100 people attended these two events, including schools who were live-streaming the session and individual school students joining from home. The students gained real-life insight into all that a career in pathology has to offer and 95% of attendees said they’d learned something new.
We also supported members and other organisers to run in-person events around the UK. We had great engagement on our social media channels with fantastic photos, videos and posts of support during the week.
The theme of our 2022 event was ‘Pathology: Past, Present and Future’ with our message focusing on pathology being at the heart of everyone’s health. Celebrations started with our virtual panel discussion exploring the history of the College, key milestones for pathology, current practices, hot topics and future advancements. The panel featured experts from different pathology specialties.
Other highlights of the week included the RCPath Book Club with Professor Heidi Larson, a pathologybased online origami workshop by Dr Lizzie Burns, and two fun and enlightening virtual pub quizzes for undergraduates. With questions gathered from our members who work in different specialty areas, these quizzes gave the students the chance to test their knowledge
27
26
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
of disease prevention, diagnosis and treatment. They were hugely popular with international students and we’re looking to develop further quizzes with international students.
## **Foundation doctors**
Safe and effective care is dependent on a sufficiently resourced workforce that can cope with both current and future demands. Our Meeting Pathology Demand workforce reports have highlighted gaps across multiple pathology specialties. Actively promoting and encouraging pathology as a career choice among foundation doctors was one of our longer-term solutions.
It's at the foundation stage that doctors consider their choices for specialty training, yet few foundation rotations contain pathology-related placements. To raise the profile of pathology among foundation doctors, we introduced several new initiatives, including the annual Foundation and Undergraduate Taster event, the Foundation Fellowship scheme and pilots of Longitudinal Integrated Foundation Training (LIFT).
The Foundation Fellowship scheme launched in 2020 and it offers foundation doctors interested in pathology, and whose rotations include a post in a pathology specialty, the opportunity to engage with the College. Benefits of the fellowship include College membership, and the chance to attend College events and educational meetings, and present at events and take part in public engagement events.
Our evaluation at the end of the scheme’s first year showed the scheme had been successful in its aim of encouraging foundation doctors to choose a career in
pathology. Of the foundation fellows who responded, 92% intended to apply for specialty training in pathology following their fellowship, with 66% stating that the fellowship had influenced their decision. Following on from this success, 25 new fellowships were launched in 2021.
Following the success of the LIFT model in aiding recruitment into general practice and increasing retainment in hard-to-recruit areas, we started discussions with the UK Foundation Schools Directors Committee and Wales Foundation School to pilot a pathology LIFT programme. As part of the programme, foundation doctors spend time in a pathology department every week (usually one day a week) for a year, gaining hands-on experience.
In August 2021, a pathology LIFT programme was launched in Wales with LIFT posts in histopathology, medical microbiology/infectious diseases, chemical pathology and forensic pathology. The feedback from LIFT doctors and their supervisors has been extremely positive and show the programme has benefits for both the foundation doctor and the department in which they work.
“I was keen to develop this placement in our health board to create bridges between the laboratory and the wards. The unexpected benefit I’ve seen already is that our F1 doctor discusses her experiences with peers on the wards and has emphasised the importance of quality information on cellular pathology request forms.”
**Dr Alison Finall, Clinical supervisor of LIFT Foundation Year 1 in histopathology, Swansea**
“This experience has improved my understanding of the complexities around death reporting and the role of the coroner’s service. This is something that I had only limited teaching on at medical school and I am looking to adopt into my own clinical practice…”
**Dr Ed David, LIFT Foundation Year 2 in forensic pathology, Cardiff**
## **Careers events**
With pathology specialties underrepresented in the medical school curriculum and foundation-year rotations, we funded a virtual pathology careers event through our Public Engagement Innovation Grant Scheme. Working with the University of Buckingham Medical School and Milton Keynes University Hospital, our aim was to inform and inspire students to become the next generation of pathologists. Final year medical students were given a series of presentations by pathologists from various specialties who were at differing points of their careers. The event made an impact, with fantastic feedback from students who felt inspired to further research pathology careers.
“The event was a fantastic learning opportunity, as pathology underpins all of medicine. Pathologists across all pathology specialties play a vital role in patient care.”
**Catherine McIlroy, Final year medical student, University of Buckingham**
## **Medical electives scheme**
We launched a new medical electives scheme to mark the College’s Diamond Jubilee. The scheme is joint funded by the College and partner societies from different disciplines, offering grants of up to £1,000 to
help support undergraduate medical and veterinary students who wish to undertake electives in pathology disciplines anywhere in the world. There are six awards covering clinical biochemistry, haematology, immunology, veterinary pathology, microbiology and cellular pathology.
## **Key achievements**
- Delivering two National Pathology Weeks to promote the incredible work of our members and raise awareness of the role of pathology throughout people’s lives.
- Successfully campaigning for greater pathology involvement and representation in the roll-out of the Genomic Medicine Service.
- Increasing the visibility of pathology among undergraduates and foundation doctors through initiatives such as the Foundation Fellowship scheme and medical electives scheme, and supporting pathology careers events funded by our Public Engagement Innovation Grant Scheme.
- Increasing engagement with parliamentarians and All-Party Parliamentary Groups to raise the profile of pathology and become the leading voice in important healthcare discussions that affect our members and their patients.
29
28
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
## We are regional
We’ve been actively pursuing the interests of our members and working to prioritise patient care across all four nations of the UK. Many of the challenges our members face are the same across England, Northern Ireland, Scotland and Wales; however, within these challenges are nuances specific to the four nations that require different approaches and solutions. We work alongside our regional councils and representatives to raise the profile of pathology and advocate for health equality, be that equal access to medication and services for patients or training programmes for trainees.
Professor Mike Osborn. Sir Michael was supportive of the College’s work to increase investment in pathology services and its workforce. We’ll foster more opportunities to work with Sir Michael in the future.
## **Regional representation**
The chairs of our regional councils work with parliamentarians, policymakers, healthcare bodies and organisations to highlight the needs of pathology services, our members and the public. They also provide a crucial link between pathologists in the regions they represent and the College. In November 2021, Dr Gareth McKeeman was elected as Chair of the Northern Ireland Regional Council, succeeding Professor Ken Mills who was in the post for five years.
During each symposium there’s a dedicated section for trainees where they can meet with Professor Mike Osborn and raise issues they’re facing. This year, trainees highlighted their concerns around exams and the impact of the pandemic on their training, with some giving talks on their personal experiences. We were able to give details of how the College can support them and outline our priorities following the results of the COVID-19 impact trainee survey.
## **Regional symposia**
The regional symposia are annual College events where members, trainees and healthcare workers have the opportunity to discuss developments in their region and upcoming themes in pathology. They are also an opportunity for policymakers and advisors to hear first-hand the issues pathologists are facing.
The symposia continue to provide the College with feedback, data and information that informs our policies for promoting and supporting pathology across all four nations.
## **Regional surgeries**
Regional representatives in England organised and hosted regional surgeries before every College Council meeting this year. These surgeries allowed members to raise concerns and discuss relevant issues specific to their regions, which were then highlighted and considered at Council meetings.
Professor Sir Michael McBride, Chief Medical Officer for Northern Ireland, attended the Northern Ireland Regional Symposium in May this year as well as holding a meeting with College President
Members attending surgeries had useful discussions around workforce and particular problems within certain regions, covering effects of the pandemic, changes to training, impending retirements and an increase in part-time working.
## **Election priorities in Northern Ireland**
In May 2022, the Northern Ireland Assembly election was held and the College launched its priorities for the next government. These focused on investment in workforce, IT and infrastructure, staff wellbeing and learning from the pandemic. We called for increased investment in equipment and transport for specialist laboratories and digital pathology. The roll-out of digital pathology will help address some of the access inequalities faced by people living in rural areas, allowing rapid referral across pathology networks and improving access to expert advice and diagnoses.
As more and more people access pathology services, recruitment and retention of staff is essential to meet demand and improve longterm resilience. More funded training places are needed and we’re calling for pay parity for new histopathology trainees in Northern Ireland in line with their counterparts in England.
We must use lessons learned
from the pandemic to future-proof pathology services and plan for further outbreaks and pandemics. The pandemic brought the role of microbiology, virology and infection control teams into sharp focus, as well as the need for leadership in areas such as stewardship of antibiotics, vaccination and disease prevention. We’re advocating for increased capacity within these
specialty areas and are ideally placed to contribute to discussions around antibiotic resistance and infectious diseases.
During the earlier phases of the pandemic, there was a drop in the number of patients seeking help and utilising screening programmes. Now we must prioritise equal access to screening for the future, focusing on transport issues and demystifying procedures.
Although the election was inconclusive, we approached the leaders of the main political parties to highlight the priorities in our manifesto. Once a government is formed, we’ll engage minsters and Members of the Legislative Assembly around our manifesto and work closely with the new government to prioritise pathology and facilitate high-quality patient care.
## **Policy and stakeholder engagement**
The College and the regional chairs have been working with kindred organisations, other partners and government agencies to push for investment, develop recovery plans and to highlight the role and importance of pathology and pathologists.
We lobbied and pressed hard for investment and, although there is still much work to be done to put the investment to work… we feel this is a step toward gaining the proper recognition of pathology informatics."
31
30
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** 2022 ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
We work alongside our regional councils and representatives to raise the profile of pathology and advocate for health equality, be that equal access to medication and services for patients or training programmes for trainees.”
Dr Bernie Croal, Chair of the College’s Scotland Regional Council, led the response to the petition urging the Scottish government to act on post-mortem activity relating to the human tissue act. We also submitted a detailed response to the target operating model for cellular pathology – a 10- to 15-year plan on how cellular pathology services will be organised and delivered.
The Scottish government’s NHS Recovery Plan failed to mention histopathology or laboratory medicine. Dr Croal wrote to the Cabinet Office secretary pointing out the pivotal importance of laboratory medicine in directing patient flow, outcomes and overall financial efficiency of the wider NHS.
This is important at a time when, typically, new plans to address waiting times and cancer backlogs frequently omit laboratory services. We suggested a concerted plan to ensure adequate laboratory services are in place, especially histopathology capacity, which will be so important for cancer pathways.
Dr Jonathan Kell, Chair of the Wales Regional Council, had a positive meeting with Eluned Morgan MS. They discussed a range of pathologyrelated issues including workforce challenges, developing scientists into consultants by increasing their access to specialist training, and the need to complete the Digital Cellular Pathology programme.
Dr Kell represents the College at the Academy of Medical Royal Colleges and Faculties in Wales. He met the Chief Medical Officer for Wales, Sir Frank Atherton, to discuss workforce issues and has been raising the profile of pathology and its role in patient care, advocating for the involvement of the College in healthcare policies and strategies.
Following Dr Kell’s contribution to the 'Priorities for healthcare in Wales forward planning' event in January 2022, he was contacted by the Care Programme about taking forward some of the ideas that came out of the meeting.
A significant investment of £120 million in LIMS and digital pathology in England was announced for the 2021/2022 financial year. We lobbied and pressed hard for investment and, although there is still much work to be done to put the investment to work – and though more funding will be required in the future – we feel this is a step toward gaining the proper recognition of pathology informatics.
## **Integrated Care Systems**
The England regional representatives continue to work with Integrated Care Systems in their respective regions. We want to be sure every system has established pathology input and are working to establish the links that will make this happen.
Dr Ali Robb, the College’s England Regional Representative for the North of England, attended the first meeting between the Academy of Medical Royal Colleges and NHSE/I on 5 April. This meeting, titled ‘What does effective clinical leadership look like in ICS?’, was organised to support the launch of the new NHSE/I Clinical and Care Professional Leadership Guidance.
There were opportunities to share some of our learning in pathology and the College will continue to contribute to these meetings.
In October 2021, the College published its commentary on the consolidation of pathology services. This paper discusses the issues that must be considered to improve the likelihood of success. It’s based on first-hand experience and feedback from our members, and includes new advice for members based on this peer-to-peer insight. We will continue to promote engagement and collaboration between each system with its pathology services.
## **Improving access to pathology careers**
The College’s partnership with the Social Mobility Foundation (SMF) helps us to reach a greater number of school students across the UK to show that a career in pathology can be for anyone. Breaking down the barriers that prevent people from pursuing a career in pathology is essential, and this is an important aspect of the College’s work.
As part of our regional Diamond Jubilee celebrations, we arranged for the MELISSA bus to visit schools across the North East of England identified by the SMF. MELISSA is a double decker bus that has been designed to deliver healthcare education and training. It was turned into a mock pathology lab to encourage students to take part in interactive experiments to learn more about the different pathology specialties. Dr Ali Robb helped to plan the events and volunteers were on hand to chat to students about their work as pathologists and healthcare scientists. The
visits were a huge success and we had great engagement from the school students who attended.
“I was really excited to visit our Social Mobility Foundation partner schools with MELISSA to give students in the North East and Cumbria a small taste of how much fun pathology can be. [It was] a great way to celebrate the College’s Diamond Jubilee. I hope others may be inspired to run events elsewhere in the North – or indeed across the UK and the world – to engage the public in the important work we do, to understand more about our pivotal role in the journey of their samples, and even to think about joining us in the future.”
**Dr Ali Robb, England Regional Representative for the North of England**
33
32
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 02** 2022 ANNUAL REPORT & ACCOUNTS OUR STRATEGY AND ACHIEVEMENTS
## We are international
The College is committed to raising international standards in pathology, engaging our members around the world, and sharing our knowledge, expertise and services as widely as possible to benefit everyone. This year has been another turbulent and challenging one for our members, with ongoing consequences of the pandemic and conflicts in Ukraine and Myanmar affecting healthcare services around the world. We’ve introduced new initiatives and have worked closely with global partners and organisations to provide much-needed support.
## **Supporting our colleagues around the world**
in close contact with the Ukraine country advisors and provided information for them to share with Ukrainian doctors seeking refuge in the UK. This includes details of the Refugee Scheme (UK), which we launched in 2021.
## **31**
international medical Our colleagues in Myanmar and graduates placed Ukraine continue to provide vital into UK training posts medical services despite living and under the College’s working in treacherous conditions. Medical Training We’ve been liaising with members, Initiative colleagues and representatives to find the best ways to help. In Myanmar, there are shortages of not only everyday medical provisions, but also medical books and learning materials. In September 2021, we received the news that our funding application to the British Medical Association (BMA) had been successful. The resources purchased with the funding were donated to medical doctors in Myanmar of all specialties and allied healthcare professionals to assist with their continued professional development.
## **Our refugee scheme**
We recognise that doctors seeking refuge in the UK face particular challenges as international medical graduates (IMGs). Our new initiative was developed to support and assist refugee pathologists located in the UK. It’s free of charge for doctors who have trained as pathologists in their home country and IMGs who have started their training in pathology but were unable to complete their training. The initiative offers refugee pathologists a free one-year membership of the College and access to a wide range of resources and events, as well as our mentorship programme.
## **International Pathology Day 2021**
We have formal links with Ukraine through our country advisors, and a long-standing memorandum of understanding with Shupyk National Medical Academy of Postgraduate Education. Our International team has been
International Pathology Day (IPD) celebrates the work of pathologists all over the world and the difference pathology makes to the lives of so many. We use this day as a platform
to share experience, knowledge and ideas and promote collaboration to improve health outcomes. Now in its eighth year, the essence of IPD has never been more important.
IPD 2021 focused on the implementation and benefits of digital pathology and artificial intelligence (AI). The growth in digital pathology and AI allows pathologists to engage and evaluate quickly and remotely with colleagues, and has the potential to aid greater international collaboration.
During the event, the issue of inequality in access to diagnostic services was discussed, with data indicating that almost 50% of the world’s population have no access to services. Solutions put forward include innovations in, and the use of, technology. There were presentations on projects assessing the viability of wholeslide imaging scanning technology in primary settings and a look into a healthcare future where informatics play a greater role in cancer care.
The roundtable topic was how digital pathology can break down international borders. The discussion raised thought-provoking information and ideas, and considered how we can achieve sustainable digital practice globally, the future of telepathology and whether digital pathology can tackle inequalities in healthcare provision.
As well as joining us for the livestreamed event on the day, our members celebrated with us across social media and showcased their work, labs and events.
International Pathology Day is an amazing chance to meet up and interact with colleagues from all around the world, to learn from each other and to develop friendships and rekindle old acquaintances, which help develop and further pathology for the benefit of patients everywhere.”
**Professor Mike Osborn President**
## **Collaborating with international partners**
## **36**
## **Cobadging**
international medical graduates sponsored for GMC registration
Over the last reporting year, we’ve proudly endorsed six different international activities through our cobadging initiative. These include Medlab Middle East in Dubai, Haem Icon Conference in Sri Lanka and the Gynaecological pathology online teaching programme for spring/ summer 2022 residents in Moldova.
## **300+**
international medical graduates attended three International Pathology School events
All year round, we get regular requests from international organisations to enter cobadging arrangements with us. We have a strict internal cobadging policy to ensure the materials we cobadge meet our standards. Cobadging agreements extend our influence and reputation globally, strengthening international relations and support for our overseas members.
## **Virtual learning resources**
Our virtual resources are developed through international collaborations and UK partnerships. They support objectives set out in our international strategy to aid the continued professional development of current and future pathologists worldwide.
35
34
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS** ANNUAL REPORT & ACCOUNTS
**SECTION 02** OUR STRATEGY AND ACHIEVEMENTS
**----- Start of picture text -----**
over
**----- End of picture text -----**
## **Key achievements**
- Live-streaming International Pathology Day 2021 to a global audience, with more than 95 people joining us from Europe, the Middle East and North Africa, South East Asia, sub-Saharan Africa and Western Pacific.
- Securing £2,000 funding for learning materials for healthcare workers in Myanmar.
- Launching our new refugee scheme to support and assist refugee pathologists in the UK.
- Collaborating with the Ghana College of Physicians and Surgeons to launch a new series of 24 video lectures to support Ghana Residents in their training and continued professional development.
over
**18,000** page views for our Ghana video lecture series in the first two months since launch
In May 2022, we launched a new series of 24 video lectures in collaboration with the Ghana College of Physicians and Surgeons and in conjunction with the Tropical Health Education Trust (THET) Ghana Workforce Health Partnership. This project was funded through the Building the Future International Workforce Programme (Ghana) by the UK Department of Health and Social Care to benefit the UK and partner country health sectors. The partnership aims to strengthen health services in lower middle-income countries as well as the NHS, and to help achieve healthcare workforce sustainability.
The video series is mapped to recently revised curricula from the Faculty of Laboratory Medicine of the Ghana College of Physicians and Surgeons and supports Ghana Residents in their training and continued professional development. These lectures, delivered by pathologists from the UK and overseas, cover four specialties – chemical pathology, haematology, histopathology and microbiology. They provide learning opportunities that support better practice, patient management and improved outcomes, helping to tackle some of the challenges at the forefront of pathology in Ghana and worldwide.
37
36
" 2022 marks the College’s Diamond Jubilee. The College owes a debt of gratitude to all the members who have volunteered over the last 60 years, from chairing committees, to becoming FRCPath examiners or helping to raise awareness of pathology. The College could not function without them.” **Professor Mike Osborn, President** 03
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 03** CELEBRATING 60 YEARS OF THE COLLEGE
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 03** CELEBRATING 60 YEARS OF THE COLLEGE
## Your College
Since it was founded in 1962, the Royal College of Pathologists has advocated for its members and for people using pathology services, to ensure the highest quality of care.
The College has continually evolved over the last 60 years to reflect changes in the profession and society. We have grown from 300 members in 1962 to over 13,000 across the world, while our commitment to our members and to the public remains the same.
essential in shaping and guiding our work. We’re focused on making the needs of our members our prime directive and, as part of our 2021–2024 strategy, will launch new initiatives that will deepen our insight into what our members want and need.
Many of our activities depend on our members volunteering. Without them, the College couldn’t function. We thank all our members who have volunteered for the College over the past 60 years. Your work has been
We will continue to work with you and for you, ensuring that pathology is at the heart of healthcare conversations.
## **Our Diamond Jubilee**
To celebrate the historic milestone of turning 60, we planned year-long celebrations with fantastic events taking place all around the UK. The Diamond Jubilee has been a great opportunity to highlight the importance of pathology in healthcare and the excellent service our members provide for patients, healthcare colleagues and the NHS.
## **Turning 60**
Tuesday 21 June 2022 was the College’s official 60th anniversary and College officers and staff had worked hard to host a selection of events on this day, including an Open Day for school students. Unfortunately, rail and tube strikes led to the postponement of the Open Day, but this didn’t dampen celebrations.
We were delighted that College Fellow Professor Sir Jonathan Van-Tam was able to present the College’s Foundation Lecture virtually. Sir Jonathan discussed his take on the pandemic and the lessons learned. He also gave advice on how to respond to and manage rapidly developing and fast-moving events with limited information, and shared his insight in dealing with media and politicians in these situations. Nearly 300 people joined us on the day, with many more viewing the lecture on our website since then.
We collaborate with organisations and stakeholders across healthcare, and it was fantastic to see such support and so many well wishes on 21 June across social media. Conversations using #RCPath60 showed great recognition of the dedicated work of our members and pathology colleagues and appreciation of how integral they are to everyone’s healthcare.
I was amazed at the variety of pets people have and the love for them which came across really strongly in the pet/owner photos. The value of veterinary pathology in establishing diagnoses and treatments for these important family members shone through.”
## **Pathology for all**
We’ve launched a new Pathologists in Profile podcast series, releasing a new episode every month throughout this special year. This series has showcased the diversity of pathology, featuring pathologists and scientists from different specialties working across the world.
**Reverend Dr Jenny McKay RCPath Pet Portrait Competition judge**
40
41
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 03** CELEBRATING 60 YEARS OF THE COLLEGE
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 03** CELEBRATING 60 YEARS OF THE COLLEGE
The RCPath Pet Portrait Competition coincided with National Pet Month and was a creative way of highlighting the value of veterinary pathology, and the breadth of pathology. We received 82 entries across social media, with an amazing array of species, including salamanders, pigeons, rabbits and dogs. There were two winning categories – cutest pet and pet that looks most like its owner.
We learn more about the paths they’ve taken and why they chose a career in pathology. To build on this, we’ve published four special issues of the _Bulletin_ , which have celebrated pathologists and scientists and our specialties, underpinning that pathology can be for anyone. We’ve had great dialogue with the Specialty Advisory Committees who provided us with articles shining spotlights on past achievements in their specialties, as well as looking at future challenges and what’s needed to overcome them.
Past-President Dr Suzy Lishman CBE took her ‘Living Autopsy’ event on tour to celebrate our Diamond Jubilee. This event has been hugely popular and successful since it was created, with one lecture receiving over 1.7 million views on our YouTube channel. Using a model playing a dead body, attendees learn about the role of pathologists and follow the process of a postmortem examination with real-life equipment used to explain this. The tour has visited Northern Ireland, Leeds, London, Edinburgh, Newcastle, Cardiff and Worcester. Regional living autopsy events have also been taking place with local pathologists in Derry, Merseyside and Tregaron. Dr Emyr Benbow delivered his living autopsy event in Welsh as part of the National Eisteddfod of Wales.
## **How you got involved**
From a classical music concert at the Liverpool Philharmonic Hall, to cycling challenges, a Pet Portrait Competition and ‘Living Autopsy’ tour, there have been so many celebrations to get involved with. We’d like to say a huge thank you to everyone that organised events and took part in what has been a fantastic year celebrating 60 years of the College and our members.
The Wales Regional Council organised the Wales Coast Path walk as part of our celebrations in Wales. On Saturday 2 July 2022, walks took place around the coast of Wales and President Professor Mike Osborn joined pathology colleagues and their family and friends on the South Wales section. The Mayor of Penarth, Cllr Laura Rochefort, joined Professor Osborn between Penarth and Cardiff Bay, discussing issues facing the pathology workforce in Wales as they walked. Dr James Davies MP also took part in the walk from Prestatyn to Rhyl along with a group from the Betsi Cadwaladr University Health Board, organised by Wales Regional Council member Dr Anu Gunavardhan.
Other events in Wales included a lecture at the Senedd sponsored by Vaughan Gething MS, Minister for the Economy, and given by Professor Meena Upadhyaya OBE – a medical geneticist and honorary professor at Cardiff University. In her lecture, Professor Upadhyaya discussed her life, work and the challenges she has faced. She is dedicated to medicine and genetics and improving opportunities for everyone. Professor Roberto La Ragione, Chair of the RCPath Veterinary Pathology Specialty Advisory Committee, delivered his Diamond Jubilee guest lecture on ‘Zoonoses: a global One Health issue’ at Swansea University as part of the Microbiology Society’s 'What's new in Cryptosporidium?' meeting. Professor La Ragione’s lecture highlighted the growing threat of zoonotic pathogens and the impact that climate change and intensive farming is having on transmission.
It was brilliant to see members across Wales taking part in the College coastal walk to highlight the amazing work pathologists do. We were grateful for the support of Cllr Laura Rochefort, Mayor of Penarth, and Dr James Davies, MP for Vale of Clwyd, and look forward to continuing to work closely on promoting the work of pathologists in Wales.”
**Dr Jonathan Kell Chair of the Wales Regional Council**
43
42
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 03** CELEBRATING 60 YEARS OF THE COLLEGE
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 03** 2022 ANNUAL REPORT & ACCOUNTS CELEBRATING 60 YEARS OF THE COLLEGE
Open Day celebrations moved to 8 September and we were delighted to be joined by 65 14–18 year olds from schools from around London. We wanted to use the Open Day to inspire and inform local young people about pathology and pathology careers, bringing school students from diverse backgrounds to the College to participate in interactive activities. It was a great opportunity for College members to communicate with young people about their work and its importance to the nation’s health.
I was honoured and privileged to be invited to speak at the Senedd about my challenging but worthwhile journey in medical genetics as part of the College’s Diamond Jubilee celebrations.”
## **Professor Meena Upadhyaya OBE**
Proceedings started with the arrival of Her Royal Highness, Birgitte Eva van Deurs Henriksen, Duchess of Gloucester, and Mr Leslie Morgan OBE, Deputy Lord Lieutenant for Tower Hamlets. We were delighted that they were able to join us for our celebrations. Professor Mike Osborn invited The Duchess of Gloucester to unveil a plaque to mark the 60th anniversary of the College and to sign the College’s visitors’ book.
In September, members of the College joined Professor Sarah Coupland, Vice President for Communications, on the Land's End to John O’Groats bike ride. They covered 1,000 miles across 12 days of cycling. The College teamed up with Cancer Research UK, Cycle Retreats, who organised the event, and Sonic Healthcare UK, who sponsored the event, to raise awareness of the role of pathology in cancer diagnostics and patient care. The funds raised for Cancer Research UK will support research carried out by pathologists and scientists to discover new therapies to treat different types of cancer. Well done to all who took part in this challenge and our virtual cycling and walking challenges earlier in the year.
45
44
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 03** CELEBRATING 60 YEARS OF THE COLLEGE
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 03** 2022 ANNUAL REPORT & ACCOUNTS CELEBRATING 60 YEARS OF THE COLLEGE
The Duchess of Gloucester and school students attended a ‘Living Autopsy’ session with Dr Suzy Lishman. With the aid of a living model, Dr Lishman talked through the step-by-step process of a postmortem examination, showing instruments used during a real autopsy. School students and their teachers enjoyed the opportunity to meet The Duchess of Gloucester before the session.
In the afternoon, students took part in nine hands-on pathology-related activities. Each student received a bag full of pathology-themed resources, including activity sheets and a bingo card, which students filled in as they went around the activities. Completed cards were collected at the end of the final round and a prize was given to two lucky students from each school.
veterinary pathology. The activities offered different ways for students to learn more about pathology – interactive quizzes, roleplay, using microscopes and 3D printers, and producing science-themed art. We are grateful to all members who volunteered their time and expertise to deliver these activities. The students had a fantastic day learning more about pathology and we’ve since received excellent feedback.
In the evening of the Open Day, we welcomed sponsors and key partners who showcased their work to guests at the President’s Annual Dinner. Thank you to our sponsors Sonic Healthcare UK, Aiforia, Sectra, Smart in Media, Agilent and the Pathological Society, and to our partners 3D LifePrints and LabTests Online.
Further events will be taking place across the UK until the end of year. In November, the College’s Scotland Regional Council will host a special Diamond Jubilee symposium at the Royal College of Surgeons Edinburgh. The symposium will highlight the vital role of laboratory services in healthcare, discussing new research and innovations, cutting-edge cardiac markers and advances in artificial intelligence. We’re delighted that we’ll be joined by Professor Sir Gregor Smith, Chief Medical Officer for Scotland, Catherine Ross, Chief Healthcare Science Officer for Scotland, and Professor Dame Anna Dominiczak, Chief Scientist (Health) for the Scottish Government.
A really inspiring day that showed the wide variety of professions in pathology. Thank you!”
The afternoon activities were delivered by members from different specialties, including neuropathology, haematology, chemical pathology, histocompatibility and immunogenetics, and
Very detailed, informative and jam-packed. I would recommend for science lovers.”
46
47
" Founded in 1962 to develop and support the evolving specialties of pathology, the College has flourished since then owing to the hard work and professionalism of you, our members. The College continues to champion the role of all our 17 specialties and our members who work to help us deliver and develop excellence in patient care.” 04 **Professor Mike Osborn, President**
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
## Our specialties
The College is very proud of all our medical and scientific colleagues working across 17 specialties and many subspecialties. Our colleagues make exceptional contributions to health at all stages of our lives. Examples of this essential work range from diagnosing inherited and acquired disease in the fetus and newborn, immunisation in childhood and adults, care of pregnant mothers, diagnoses, investigation and treatment of a multitude of disorders, infections and cancers together with screening programmes right through to post-mortem examinations that inform the care of the living. We have briefly outlined the key roles of each specialty with a further spotlight on just some of the ongoing work in the clinical case studies in the next few pages.
## **Cellular pathology**
## **Forensic pathology**
Cellular pathology includes many subspecialties, including cytopathology and dermatopathology. Cellular pathologists are doctors and scientists who diagnose and study diseases including cancer and inflammatory diseases, such as ulcerative colitis, in tissues and organs. Cytopathologists diagnose cervical cancers through the screening of cells. Examination by microscope of a small biopsy or tumour can provide the diagnosis but, increasingly, this is supplemented by DNA examination of cancers to tailor treatment.
Forensic pathologists perform medico-legal post-mortem examinations to determine the cause of death, including cases where a crime is suspected. They collect, examine and interpret tissue specimens under the microscope, as well as documenting and interpreting injuries, including on living victims. They provide scientifically objective expert reports for the police, coroners, procurators fiscal and solicitors and give expert evidence in crown, family and coroners' courts among others.
## **Genetics and genomics**
## **Chemical pathology**
As advances in technology have allowed us to study DNA in ever greater detail, genetics and genomic medicine have become an important weapon in the fight against disease. Doctors and scientists working in genetics diagnose inherited diseases and advise families on treatment. Genomic testing also contributes to the better understanding of infection, including mapping of the COVID-19 pandemic.
Chemical pathologists and clinical biochemists monitor bodily fluids like blood and urine to detect important changes in the body’s chemistry. They play a key role in diagnosing and monitoring patients with a wide variety of illnesses, from high cholesterol to thinning bones. Chemical pathologists interact with patients at several different points through their treatment journeys – they investigate test results and meet patients in person to support their treatment.
Genomic medicine is at the forefront of transforming patients’ lives by enabling a quicker diagnosis for patients with a rare
treatment forms an important
disease; matching people to the most effective medications and interventions; and increasing the number of people surviving cancer each year because of faster, accurate diagnosis and tailored treatment with targeted therapies.
part of therapy and/or prevention. Immunologists also specialise in the diagnosis and treatment of allergies. This specialty is playing a key role in better understanding the immunological response to SARSCoV-2, including the development of potential therapies and vaccines.
## **Haematology**
Haematologists are experts in blood cells, including those circulating round the body and in the blood cell factories of the bone marrow. Haematologists diagnose and treat malignancies such as leukaemia and anaemias like sickle cell disease. They also deal with abnormalities of the blood clotting system, such as haemophilia. Haematologists care directly for patients on hospital wards and out-patient clinics, and carry out diagnostic work in laboratories.
## **Microbiology**
Medical microbiologists support and oversee the prevention, diagnosis and treatment of illness caused by microorganisms such as bacteria. They give advice on clinical and laboratory diagnosis of infection, identify the best treatment for infectious diseases and monitor patients following treatment. They also ensure antibiotics are prescribed and used appropriately so patients receive the best treatments and to minimise antimicrobial resistance.
## **Histocompatibility and immunogenetics**
Microbiologists have been at the forefront of the response to the SARSCoV-2 pandemic, advising on infection prevention and control measures, public and occupational health, strategic planning and overseeing COVID-19 testing and diagnosis in centres where there is no on-site virologist.
Histocompatibility and immunogenetics (H&I) is the study and testing of the genes and proteins that are important in the matching of organ and bone marrow transplant donors with recipients. H&I scientists ensure that transplanted organs and cells are compatible with the recipient to lessen the chances of rejection. They also support transfusion of platelets and granulocytes and are involved in investigations into transfusion reactions. H&I tests are important in the diagnosis of inflammatory diseases and can help predict adverse reactions to drugs used to treat disease, e.g. HIV.
## **Immunology**
Immunologists deal with the study, diagnosis and management of people with disordered immune systems and immune deficiency. They advise on conditions in which immunological
50
51
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS** ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS** ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
## **Molecular pathology**
Pathologists working in this specialty examine molecules, particularly DNA, within organs, tissues or bodily fluids to study and diagnose diseases. Molecular tests check for specific changes in genes or chromosomes that can cause disease, such as cancer and infectious diseases. Molecular pathologists have an important role in personalised medicine, which identifies patients that can benefit from targeted therapies based on the molecular characteristics of the tumour present.
## **Neuropathology**
Neuropathology is concerned with diagnosing and investigating diseases in the nervous system, i.e. brain, spinal cord and nerves, as well as the muscles of the skeleton. These include a wide range of disorders, such as tumours, inflammatory disorders,
infections and genetic diseases. Neuropathologists use microscopes to examine samples of tissues but, in recent years, findings from molecular tests have been increasingly incorporated into their reports, for example for brain tumours. This provides much more detailed information to the clinicians with whom they work closely.
## **Oral and maxillofacial pathology**
This lesser-known branch of dentistry – oral and maxillofacial pathology – is concerned with diagnosing diseases in the head, neck, mouth, jaws and face. Oral and maxillofacial pathologists use soft tissue and bone biopsies alongside information from dental examinations and X-rays to investigate patients’ cases. They are also involved in research into the development of treatments for head and neck cancer and the investigation of the genetic causes of developmental diseases.
## **Paediatric and perinatal pathology**
Paediatric pathologists diagnose, investigate and monitor disease in children from conception up to 18 years of age. This includes areas such as genetic disorders, congenital diseases, cancers, disorders of metabolism, inflammatory disorders and infection. They are experts in a range of pathology specialties, such as cellular pathology, laboratory medicine and medico-legal pathology. Perinatal pathologists diagnose and investigate disease processes that affect unborn babies, newborns and infants. They investigate causes of pregnancy loss, miscarriage, stillbirth and neonatal disease. They are experts in pathology involving the placenta.
## **Reproductive science**
Using increasingly sophisticated technology, scientists working in reproductive science can give hope to couples who are having trouble conceiving. They are experts in diagnosing infertility, as well as investigating, offering advice and insight on treatment options and delivering treatments, such as in vitro fertilisation.
## **Toxicology**
Toxicologists are scientists who work across a broad range of environments in healthcare. In hospitals, they analyse samples from patients who have, for example, taken recreational drugs or overdoses of prescription medicines. They also advise public health bodies and industry on chemical and environmental hazards and on drug safety.
## **Transfusion medicine**
Transfusion doctors and scientists are haematologists who specialise in transfusion medicine. They make sure that every patient who needs a transfusion is matched with blood from a suitable donor. They oversee the health and wellbeing of donors, the testing of blood for infections, the management of hospital blood stocks and promotion of the safe and appropriate clinical use of blood and components. Transfusion staff participate in and contribute to haemovigilance activities promoting patient safety.
## **Veterinary pathology**
Veterinary pathologists work in animal disease surveillance, prevention, diagnosis and treatment. They play a key role in the development of safe and effective medicines and vaccines for animals
and humans. They investigate diseases in pets and farm animals, as well as exotic species. They also contribute to animal conservation and protection, and public health.
## **Virology**
Virologists are doctors and scientists who oversee the diagnosis, management and treatment of patients with viral infections, from common viruses like chickenpox to emerging infections like Zika and Ebola. Virologists are also involved in public health – studying and advising on infections spreading globally as a result of travel and climate change. Some virologists specialise in vaccine development. This specialty has been particularly recognised in making an enormous contribution to COVID-19 testing and diagnosis, which have been essential to the care of healthcare staff and patients throughout the pandemic.
53
52
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**----- Start of picture text -----**
CAS E STU DY
**----- End of picture text -----**
## Implementing a newborn screening programme: our experience in Kaduna State, Nigeria
Newborn screening programmes for sickle cell disorder ensure early diagnosis, allowing preventative measures to be established early in childhood and reducing the likelihood of major health complications. Here, Dr Ifeoma Ijei-Enesi, Dr Livingstone Dogara and Dr Psalm Baba Inusa describe how their screening programme has overcome challenges to improve diagnostic and treatment services for patients with sickle cell disorder.
Sub-Saharan Africa accounts for more than 80% of the over 400,000 sickle cell disorder (SCD) annual births globally, with Nigeria having the most cases. Despite the significant public health implications, no African country has implemented universal newborn screening (NBS) similar to national childhood immunisation programmes. **[1]** NBS is essential for early diagnosis and the initiation of basic health intervention strategies and steps to prevent diseases like malaria, to reduce illness and death. **[2]**
The African Research and Innovative Initiative for Sickle Cell Education (ARISE), an EU-funded project (www.ariseinitiative.org), is working with state, local and international partners to increase research, diagnostic and clinical management capacity throughout the healthcare system. The aim is to bridge the screening gap by screening 10,000 infants annually.
## **Amina’s story**
Amina’s* parents drove 11.2 km across the Kaduna metropolis to our facility, a tertiary hospital in the heart of the city. They had been referred for specialist care for their son aged almost four. Amina, his three-month-old sister, was offered screening as she was an at-risk infant.
Experts in Africa have identified a complexity of factors contributing to the challenges faced in initiating, operating and expanding NBS programmes. There is consensus that the government’s role in the design, implementation, funding and integration of NBS programmes for SCD into public health systems can influence the sustainability.
Amina underwent dried blood spot sampling, whereby a small volume of blood was collected from Amina onto a piece of absorbent paper called a Guthrie card. The blood dried on the paper before being packaged and sent to a screening laboratory in Kafanchan, a town about three hours away from the metropolis. The lab uses isoelectric focusing, which is a cost-effective technology that separates
The north-western state of Kaduna has a population and density of 8 million and 183.1/km[2] , respectively (as at 2016). **[3]** It is here that our young NBS programme exists at a sub-governmental level in a small network of rural and urban facilities offering tiered healthcare.
proteins, to identify abnormal types of haemoglobin associated with SCD. **[4,5]**
for tests and equipment. We have been able to provide service and training to primary healthcare centers to help improve the services provided and set standards. To further reduce delays and promptly identify and address challenges along the screening pathway, we established an additional NBS laboratory, implemented regular twice-monthly meetings and facilitated a review process. We have reduced our turn-around-time and babies are now enrolled into clinical care within four to six weeks of the blood spot being taken.
Unfortunately, in a country facing the challenges of incessant power outages, supply chain interruptions, difficult travel terrain and insecurity, the testing platform was experiencing equipment downtime. It was six months before Amina’s results were received on-site. The parents were contacted by phone within 24 hours of receipt, but they were unable to make a physical appointment until three weeks later due to paternal schedule conflicts.
Amina’s story depicts the myriad of challenges faced in providing diagnostic and therapeutic treatments for people with SCD in low- and middleincome countries and some strategies to overcome such barriers. With her parents eager to partner with us to provide the best possible care for her, I know we haven’t seen the last of that little girl and I’m privileged to have been a small part of her story.
Amina was now one year old. She had developed symptoms at four months and the results showed she had SCD like her older brother. Despite the delay in obtaining her results, the parents’ concerns were allayed by education about how her disorder could be managed and were both relieved and delighted to hear about our care plan for her going forward. She is currently enrolled at our facility receiving malaria and pneumococcal prophylaxis, folic acid, vaccinations and health checks.
_Acknowledgements to Monica Shuaibu and Janet Yakubu._
We have since secured increased government commitment and American Society of HematologyConsortium on Newborn Screening in Africa (ASH-CONSA) laboratory support for resources
*The child’s name has been changed to maintain confidentiality.
Sickle cell disorder affects the nature of haemaglobin (a special protein that carries oxygen and is found in red blood cells). Normal red blood cells are doughnut-shaped – red blood cells affected by sickle cell disorder become sticky and rigid when they lose their oxygen and become sickle-shaped, like a crescent moon. This causes them to block blood vessels, leading to symptoms that are often painful, or be destroyed too early sometimes requiring a blood transfusion. It's a lifelong condition and early diagnosis means treatment can start promptly. There are treatments to manage sickle cell disease, but a cure is not widely available.
**References:** References can be found online: - www.rcpath.org/profession/publications/annual reports.html
55
54
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
CAS E STU DY
## Improving blood matching for transfusions in patients with sickle cell disorder
The transfusion of red blood cells may be a one-off event, or it may be required every few weeks over many years, for example for people with an inherited anaemia such as sickle cell disorder. Here Dr Sara Trompeter, a consultant haematologist, discusses the challenges in matching blood for transfusions and advances in red cell genotyping through the Haem-Match project.
## **Matching blood**
Alloimmunisation can be dangerous, because if the patient is transfused subsequently with blood containing the antigen that caused the antibody to form, there is a risk that the immune system of the patient will attack the transfused cells, causing a haemolytic reaction that can be fatal. We know that some people who receive transfusions (such as those with sickle cell disorder and thalassaemia) are more likely to form antibodies than patients with a condition requiring a one-off transfusion.
Red blood cells – the cells that carry oxygen around the body – have labels on their surfaces, known as antigens or blood groups, which we inherit genetically from our parents. Blood is selected for transfusion according to the blood groups of the donor and the blood group of the recipient – we call this ‘matching’. There are over 2 million units of blood donated a year in the UK. There are over 200 blood groups so matching for everything every time is not feasible. Currently, we routinely provide blood matched for the ABO blood groups and also for RhD (a protein found on the surface of red blood cells; previously also referred to as Rhesus).
When [Ama] was pregnant … there were only two units of blood available for her nationally. If she were to have had a serious sicklerelated complication, she would have likely needed at least eight units of blood to treat her.”
## **The consequences of unmatched blood groups**
For most people undergoing a blood transfusion, provided they are ABO and RhD matched, there are no complications. However, a patient may form an antibody against a blood group if the red cells of the donor have an antigen that is ‘foreign’ to the patient (i.e. if the red cells of the donor have a blood group that the red cells of the recipient do not). This is known as alloimmunisation.
To reduce the risk of antibody formation, blood for regularly transfused patients is matched at present by considering other Rh antigens, for example C, c, E, e and the K blood groups in addition to the A, B, O and D blood groups. Despite this, around 17% of
such people do make antibodies to the other blood groups that we do not match and many will have severe transfusion reactions. This can result in real difficulty in getting blood for them.
## **Ama’s story**
Ama has sickle cell disorder and developed antibodies following transfusion. When she was pregnant in 2018 there were only two units of blood available for her nationally. If she were to have had a serious sickle-related complication such as a chest syndrome, she would have likely needed at least eight units of blood to treat her. We met with Ama and had a conversation about the impact of alloimmunisation on her. She spoke candidly about the anxiety that she experienced during her pregnancy. She discussed the enormous lengths the clinical and laboratory staff in the hospital and NHS Blood and Transplant (NHSBT) – the national blood service for England – went to ensure that suitable blood was made available for her should she have needed it.
Ama spoke about her hopes … for her children who also have sickle cell disorder. Ama is hopeful that they might not form antibodies and be in such a vulnerable position as herself. This is a major aim of Haem-Match.”
We spoke about the rare donor panel – a group of donors with rare blood groups who are supported by NHSBT to donate, sometimes in an emergency – whose selflessness she was particularly touched by. The National Frozen Blood Bank in Liverpool and teams in NHSBT such as the red cell immunohaematology (RCI) teams and the International Blood Group Reference Laboratory (IBGRL) undertake testing and research to support those who are difficult to transfuse. Ama spoke about her hopes for the future, particularly for her children who also have sickle cell disorder. Ama is hopeful that they might not form antibodies and be in such a vulnerable position as herself. This is a major aim of our research project Haem-Match.
## **What is Haem-Match?**
Haem-Match aims to provide blood for transfusion that is more precisely matched to patients’ blood groups, known as extended (red cell antigen) matching. In doing so, we can reduce the risk of harm caused by transfusion (for example antibody formation, alloimmunisation and transfusion reactions), streamline the allocation of precisely genetically matched units to patients with complicated transfusion needs, and reduce waste and improve efficiency in the collection and allocation of blood units.
Although the project initially focuses on reducing the risk of blood transfusion treatment for people with sickle cell disorder, we hope to expand this to people with other transfusion-dependent anaemias such as thalassaemia and myelodysplastic syndrome. You can read more about Haem-Match here: www.haemmatch.co.uk.
56
57
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
CAS E STU DY
## Finding a novel cause of primary immunodeficiency
Clinical immunologists specialise in diagnosing and treating patients with inherited or acquired failures of the immune systems that lead to infections and autoimmune complications. When the cause of an immune system disorder is unknown, clinical trials and research can be vital in providing answers. Here, Dr Sinisa Savic describes how a novel cause of primary immunodeficiency was discovered.
Maurice was well as a child but began suffering with frequent chest infections from his midteens. At 15 years old, he recalled being treated for pneumonia. It was not until he was 19 years old that he came to the attention of the clinical immunology department at St James’s University Hospital in Leeds. His referral was triggered by a finding of very low levels of immunoglobulins (antibodies) in his blood, following routine investigations for chronic diarrhoea.
they did not respond properly. Maurice had no family history of immunodeficiency to suggest a genetic cause for his condition, but neither did his condition fit with one of the genetic types of primary immunodeficiency known about at time, since his disease onset was so late. Therefore, he was given a diagnosis of common variable immunodeficiency – a diagnostic label used for some primary immunodeficiencies of unknown cause. He was started on immunoglobulin replacement therapy and has remained on this treatment ever since.
As medical science continues to advance, the technology for correcting genetic conditions will become more readily available.”
In 2014, Maurice was invited to take part in a local study that aimed to improve the diagnosis of primary immunodeficiencies through the use of advanced genetic testing. Maurice was found to have unique changes within his genetic code, in a gene called _CRACR2A_ . Changes in this gene had not previously been linked to any specific health conditions, but studies in mice had shown that when this gene was deleted, it resulted in abnormal function of the immune system. In particular, it led to the reduced capacity of CD4 T cells to respond to infection, similar to what was seen when testing Maurice’s lymphocytes.
Once he was under the care of the clinical immunology team, detailed investigations of his immune system were arranged. This included studying particular types of white blood cells, mainly lymphocytes, to determine more precisely the type of immunodeficiency Maurice was suffering from. These tests showed that his immune system was not producing enough immunoglobulin or a specific type of lymphocyte called a CD4 T cell. In addition, when his lymphocytes were activated by signals mimicking natural infection,
Following this initial genetic discovery, it took several years to complete the testing required to provide definitive proof that the changes
in Maurice’s genetic code were the cause of his immunodeficiency. In part, this is because Maurice is the only person in the world where these specific genetic changes have been associated with immunodeficiency. It has been almost 20 years from the onset of symptoms to the point where we were able to establish a precise diagnosis for Maurice’s condition. Over this period of time, many new immunodeficiency conditions have been identified and genetic testing is now part of the routine diagnostic work-up for patients presenting with suspected immunodeficiency. We have more sophisticated ways in which to study the immune system and the length of time from becoming ill to getting a precise diagnosis is ever shorter for our patients.
None of this research would be possible without Maurice and others like him volunteering to take part in studies and help advance medical science."
The discovery of a genetic cause for Maurice’s immunodeficiency did not result in any immediate change to his treatment. However, simply having an explanation helps him to cope with this longterm condition and he is now better able to make informed decisions about his career and family plans. As medical science continues to advance, the technology for correcting genetic conditions will become more readily available. Since this will only be relevant in patients with a precise genetic diagnosis, the importance of such diagnoses cannot be overemphasised.
None of this research would be possible without Maurice and others like him volunteering to take part in studies and help advance medical science. The practice of clinical immunology has always been closely linked to basic translational research. This is probably why the recent update (2022) from the International Union of Immunological Societies can list 485 separate human inborn errors of immunity, with 50 of these identified in the last two years.
59
58
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS SECTION 04** 2022 ANNUAL REPORT & ACCOUNTS OUR SPECIALTIES AND CASE STUDIES
CAS E STU DY
## Combining dentistry and pathology to diagnose and treat oral cancer
Oral and maxillofacial pathologists are dentists by degree qualification and take a further training programme and FRCPath examination that is similar to their medically qualified colleagues. Their dentistry background provides them with in-depth knowledge of the complex processes that are involved in the development of teeth. Here, Dr Gillian Hall describes an unusual case of a tumour arising from the lining of a dental cyst.
In more than a dozen years as a consultant, this is the first time that I have seen a carcinoma arising in [a dental cyst] (and likely the last).”
I am sure that most people will be aware of the troubles that teeth can cause, but may not know that cellular remnants and clusters of residual cells from tooth formation lay dormant in our jaws, and have the ability to wake up, proliferate and form lesions in later life. These include common cysts, which occur around unerupted/ partially erupted wisdom teeth and inflammatory cysts that appear around the roots of teeth that have been traumatised or are decayed. These lesions form much of the daily work of an oral and maxillofacial pathologist and are resolved when the tooth causing the problem is removed or if tooth-saving dental procedures are performed.
Considering that these cluster of residual cells are present within the jaws and the soft tissues of the gums as scattered groups of rarely more than ten cells, the diversity of appearances of the lesions that they can become is astonishing. The most recent 2022 WHO publication lists 11 types of cyst, 16 benign and seven malignant tumours. In the UK population, less than 6% of tumours that develop in the tissues responsible for tooth formation are malignant and the less worrisome cysts are at least five-times more common than all the benign and malignant tumours combined.
In some cases, a sample of tissue is taken and sent to us for diagnosis. Occasionally, the clinical and radiological appearances may not be entirely typical or explainable as one of these common cysts, and pathological examination of the tissue is essential. Whatever the scenario, we examine the tissue cells using a microscope, searching for evidence that might signify a more worrying diagnosis, namely one of the rare types of tumours that these cells have the capability to form.
In late 2021, tissue was submitted for diagnosis of a white growth that was seen on the gum of a 59-year-old woman, behind her last standing lower molar tooth. She did have a
past history of tobacco use, so she could be considered as at risk from oral cavity cancer.
An urgent biopsy was performed. When I examined the tissue under the microscope, I could see that the squamous epithelial cells (the cell type that forms the lining of the mouth) weren’t typical. From this investigation, it wasn’t possible to show there was invasive growth, which would have indicated a diagnosis of cancer.
In the UK population, less than 6% of tumours that develop in the tissues responsible for tooth formation are malignant…”
The clinical appearances were, however, highly suspicious, and there were features of concern in the bone that were visible after examination using radiography. To complicate matters, the scans revealed a buried wisdom tooth immediately below the abnormal area around which was a sizable cyst.
A limited surgical removal of the lesion would be considered the ideal treatment, but the presence of the tooth and cyst meant this was not possible. A full thickness segment of the jaw, to include the lesion, buried tooth and cyst was removed.
The macroscopic appearances after slicing the segment using a bandsaw suggested an inseparable relationship between the proliferative lesion on the gum and the cyst, which encased the unerupted tooth. Examination of slides showed the lesion to be a cancer that had arisen from the lining of the cyst.
…our job is to provide the precise diagnosis, thus give clarity to the patient and their clinical team and to inform the right course of treatment.”
The reported incidence of the tumours that arise from the previously described tooth-forming cell clusters is 0.5 per 100,000, which in the current UK population would be 350 cases per year, and if less than 6% are cancerous, then this would amount to just 21 per year nationally.
The tumour was low grade and cut out with good margins to ensure no tumorous cells were left. There were no aggressive features and no spread to the lymph nodes of the patient’s neck. The prognosis for this patient based on these findings is excellent and no chemotherapy or radiotherapy was needed.
Before the reader dashes for an emergency trip to the dentist to check their wisdom teeth, it should be noted that I probably see a dozen dental cysts or more every week. In more than a dozen years as a consultant, this is the first time that I have seen a carcinoma arising in one (and likely the last).
Dentists are always on the lookout for soft tissue growths and check for abnormalities on X-rays that could indicate the presence of a dental cyst or tumour, and will refer to a specialist when something is amiss.
Likewise, the histopathologist, whatever their background, is forever looking for that once in a career rarity that makes our job so fascinating. But, far more importantly, our job is to provide the precise diagnosis, thus give clarity to the patient and their clinical team and to inform the right course of treatment.
61
60
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
CAS E STU DY
## Multiple myeloma: entering a new era of genetics
Patients with multiple myeloma – a type of bone marrow cancer – often have poor outcomes. Professor Guy Pratt, a clinical haematologist, explains how genetic testing can be used to aid decisions around the best treatment for patients, ultimately improving survival rates.
the fitness of the patients for intensive treatment and whether severe renal failure is present. For several years it has been recognised that one in four patients with myeloma have a tumour with adverse genetic abnormalities (causing highrisk myeloma). High-risk myeloma is associated with poorer outcomes and a median survival of three years with conventional approaches.
Multiple myeloma is a haematological cancer of plasma cells (a type of white blood cell) that arises in the bone marrow. Patients have symptoms such as pain, infections, anaemia and renal impairment. It affects over 20,000 people in the UK currently, with 5,000 new cases diagnosed each year. Late diagnosis remains a problem since patients often present with non-specific symptoms and it is relatively uncommon.
Myeloma management has lagged behind other blood cancers in terms of genetic testing and the use of genetics in treatment decisions and discussions with patients around their outlook. The genetics of myeloma is complex and more heterogeneous (diverse) compared with other haematological cancers. However, it is known that the presence of two or more certain genetic abnormalities is associated with a worse outlook.
Over the last 20 years there have been significant improvements in the availability of novel treatment options. This has led to a marked improvement in outcomes. Despite this, multiple myeloma remains an ultimately fatal condition.
We are entering a new era where the results of genetic testing will increasingly be used in treatment decisions … for patients with myeloma.”
Myeloma UK trial 9 was the first molecularly stratified (where patients were grouped according to the molecular characteristics of their cancer) prospective trial that aimed to improve the outcome for patients with high-risk myeloma. Between 2017 and 2019, 472 patients with suspected high-risk myeloma from 39 UK NHS hospitals were screened for genetic abnormalities. Patients found to have high-risk disease genetically were offered participation in the trial.
Patients receive repeated treatments over years before the disease becomes resistant to treatment or patients reach a point where they cannot tolerate further treatment. Traditionally, initial treatment decisions have been based on
In this trial, combinations of multiple novel agents were used during induction therapy (the first therapeutic measures taken to treat a disease) and after a stem cell transplant (where a patient receives healthy stem cells from a donor to replace damaged cells). These agents were used for the 18-month consolidation period post-transplant, followed by maintenance with two drugs. This was in contrast to current treatment regimens that use limited novel agents with a very short duration of consolidation and maintenance with just one drug.
Myeloma UK trial 9 has highlighted that outcomes for patients with high-risk genetics can be significantly improved by maintaining patients on a combination of novel agents indefinitely…”
A total of 117 high-risk patients received intensive therapy with combinations of multiple drugs before, during and after the stem cell transplant. The trial demonstrated that progression-free survival at 18 months was superior for high-risk patients treated in this study compared with patients treated with current treatment strategies. The use of bettertolerated drugs helped to reduce toxicity and the regimen was well tolerated. Myeloma UK trial 9 has highlighted that outcomes for patients with high-risk genetics can be significantly improved by maintaining patients on a combination of novel agents indefinitely and that such an approach is well tolerated with newer drugs.
## **Sara’s story**
Sara was 35 years old when she was diagnosed with multiple myeloma in 2018. She’d had back pain for at least a year that had worsened, limiting her mobility and requiring her to be off work. Imaging investigations showed wedge compression fractures in her spine and other bone lesions, her blood showed the presence of a myeloma protein and a bone marrow biopsy confirmed myeloma. Sara agreed to have her bone marrow screened in the Myeloma UK 9 screening trial and it showed high-risk disease.
Sara entered the trial and has tolerated treatment well including a stem cell transplant in June 2019. Four years after starting treatment her myeloma remains in a deep remission. Another feature of the Myeloma UK 9 trial is that a large percentage of patients who achieve complete remission continue in prolonged deep remission when using a combination of lenalidomide and daratumumab (drugs used to treat cancer) as a maintenance treatment.
We are entering a new era where the results of genetic testing will increasingly be used in treatment decisions as we hopefully head towards more effective personalised medicine for patients with myeloma. Indeed, examples are emerging where the genetic results of patients with myeloma have indicated high response rates to specific drugs.
63
62
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**----- Start of picture text -----**
CAS E STU DY
**----- End of picture text -----**
## Tackling bird flu in the UK
The UK and Europe are currently tackling the longest and largest series of avian influenza outbreaks, posing a serious threat to wild bird populations and people’s livelihoods. Here, veterinary virologist Dr Sharon Brookes describes the work of the Animal and Plant Health Agency in response to this outbreak.
Avian flu is causing systemic disease in birds globally. In the UK, threatened bird species like roseate terns, puffins, seal eagles and hen harriers have been affected, as well as poultry farms and wild bird populations.
the field. These activities support decisions to enable fast and effective control of this notifiable disease. Surveillance is also necessary for the UK to become disease free again (in seasons prior to this one) and be able to re-start international trade of poultry products. The APHA have expert virologists, bioinformaticians, epidemiologists, veterinarians, field staff, risk analysts and modellers to coordinate our scientific response to help stop further spread of this important disease.
As a veterinary virologist based at the Animal and Plant Health Agency (APHA; in the Department for Environment Food & Rural Affairs), with a primary interest in how viruses develop and cause disease, my work has encompassed disease pathology of a range of host animal species working closely with our veterinary pathologists. Most of my time at the APHA has involved working with animal influenza A viruses, both swine and bird flu.
The last few years have seen an escalation of AIV incursions infecting more poultry, a wider range of wild bird species and even crossing over to mammals, including a single case in humans. As of 15 September 2022, we were at day 321 of the ongoing outbreak with 144 cases declared and over 1,649 detections of AIV in wild birds in 392 locations, involving 57 species in 82 counties, including conservation and predator bird species. **[1]** This represents a significantly greater detection of HPAIV in poultry and captive birds than previously reported in 2020–2021 (26 cases) and 2016–2017 (13 cases).
Avian influenza viruses (AIV) cause bird flu in poultry and wild birds. The arrival of AIV is normally connected to wild bird migration in the autumn and winter months. The current 2021/22 outbreak of H5N1 (a strain with high pathogenicity [HP], i.e. a high ability to induce disease) started at the end of October 2021. The peak risk period for AI outbreaks is between December and February and case numbers reduce with in-country population control of infected poultry and kept birds (pets and collections) and decline of incoming migratory birds.
Globally, HPAIV H5N1 is widely dispersed, causing outbreaks in Europe, North America, Asia and Africa, affecting people’s livelihoods and wildlife conservation. It is important to raise awareness of how to diagnose the disease through an understanding of how it affects the birds’ organs and tissues. This will improve investigations, for example realising pathognomonic signs following natural infection. HPAIV H5N1 in poultry species,
At the APHA we are responsible for UK government science expertise on AIV and for providing all the testing and diagnoses. APHA offers the scientific evidence for disease confirmation and undertakes the epidemiological response to the disease in
such as chickens, turkeys, ducks or geese, or captive or wild birds, including mute swans, tufted ducks, jackdaws or white-tailed eagles, typically causes tissue damage in the pancreas and spleen. **[2]** Interestingly, the disease usually appears to be more severe in poultry than wild waterfowl.
The last few years have seen an escalation of [avian influenza virus] incursions infecting more poultry, a wider range of wild bird species and even crossing over to mammals, including a single case in humans."
The close linkages between the APHA and the Public Health Agency (UK Health Security Agency) have facilitated active surveillance among people exposed to the HPAIV, which enabled the detection of HPAIV H5N1 in an asymptomatic human case Russia during the current avian influenza season. **[3]** reported infection in poultry workers with H5N8 during 2021. **[4]** However, it should be noted that, despite extensive global avian–human interaction, cases of H5 AIV detected in people are very rare.
H5 AIVs have also been detected in mammals. HPAI H5N1 virus infections (2021–2022) have been detected in wild red foxes across Europe. **[5]** In late 2020, a wildlife rehabilitation centre in the UK reported that there had been deaths of young seals and a red fox. These deaths were associated with HPAI H5N8 infection. **[6]** In August 2021, HPAIV H5N8 infection was detected in three adult harbour/common seals found at the German North Sea coast. **[7]** Interestingly, neurological signs were reported for several of these mammals and the virus was detected in brain tissue with limited or no detection in the respiratory tract and other organs. For mammals, the most probable route of infection is consumption of contaminated water, faeces or scavenged infected bird carcasses. In North America, the mammals infected with H5 AIV include red fox, coyote, skunks, otters, a lynx and a polecat.
These cases highlight the importance of HPAIV disease investigations and surveillance in poultry and wild birds, and mammals including humans, to monitor the hazard, threat and risks to safeguard animal, environmental and public health.
_With thanks to Professor Ian H Brown (avian influenza disease consultant), Dr Alejandro Nuñez and Fabian ZX Lean (veterinary pathologists) and Mr Scott Reid (avian virology lead from APHA)._
**References:** References can be found online: www.rcpath.org/profession/publications/annual-reports.html. For additional information, see https://aphascience.blog.gov.uk/
65
64
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 04** OUR SPECIALTIES AND CASE STUDIES
CAS E STU DY
## Advances in the management of thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura is an acute life-threatening condition with a high mortality rate. Here, consultant haematologist Professor Marie Scully MBE explains how recent advances in its treatment and management have improved the outcomes for patients with this condition.
Thrombotic thrombocytopenic purpura (TTP) is life-threatening and a medical emergency. It presents rapidly around 40 years of age and is more common in females. Without treatment, the mortality rate is over 90%. Around 90% of cases are due to patients forming antibodies to the metalloprotease enzyme ADAMTS 13 – this is known as immune TTP. The other 10% of cases have a genetic cause (hereditary deficiency of ADAMTS 13) known as congenital TTP.
Clinically, the presentation of TTP may be heterogeneous (diverse) but it is usually associated with low levels of blood platelets (thrombocytopenia) and microangiopathic haemolytic anaemia (a type of anaemia resulting from damage to red blood cells when blood vessels are blocked).
## **Mark’s story**
Mark, a 45-year-old male of Afro-Caribbean heritage, presented on a Saturday night with vomiting, confusion and a rapid decrease in his Glasgow Coma Scale (GCS) that measures the level of consciousness in a patient. He required admission to the intensive care unit (ICU) following intubation and ventilation. He was transferred for urgent plasma exchange (PEX) following a presumed diagnosis of TTP. In PEX, diseased plasma is separated and removed from the blood and replaced with donor plasma. A blood film confirmed thrombocytopenia, fragmented red blood cells and polychromasia (the latter indicating a high number of immature red blood cells in the bloodstream seen in haemolytic anaemia). A diagnosis of TTP was confirmed through analysis of ADAMTS 13 activity levels, which were severely reduced, and antibodies to ADAMTS 13, which were very high.
Thrombotic thrombocytopenic purpura is a medical emergency … Without treatment, the mortality rate is over 90%.”
ADAMTS 13 is a protein that plays an essential role in the regulation of blood clotting by cleavage of von Willebrand factor (VWF) with splitting of ultra-large VWF multimers into smaller VWF multimers. In TTP, there is a deficiency of ADAMTS 13, resulting in the accumulation of ultra-large VWF multimers, which have increased platelet binding. This results in microvascular thrombosis with blockage of small blood vessels and end organ damage.
Mark’s presentation was severe and his prognosis was poor even with treatment. He had neurological involvement with confusion and reduced GCS on admission and raised levels of troponin – a protein released into the bloodstream when the heart muscle is damaged.
Mark received PEX immediately on transfer and intravenous methylprednisolone, a drug used to treat inflammation and immune reactions in various organs. Before his second PEX on the day of admission and following confirmation of severe ADAMTS 13 deficiency, Mark was started on caplacizumab (an antibody fragment that targets VWF, preventing it from binding to platelets and causing blockages), which he then received daily. As well as receiving daily PEX until his platelet count had increased, Mark started rituximab on day 2 of admission and oral prednisolone. Both rituximab and prednisolone inhibit the production of anti-ADAMTS 13 antibodies, thus increasing ADAMTS 13 activity. Mark was extubated within 48 hours and discharged with continued treatment as an out-patient on day 8.
The identification of the immune basis of thrombotic thrombocytopenic purpura has resulted in the introduction of appropriate immunosuppressive treatment that reduces the time patients spend in hospital receiving treatment.”
## **Advances in TTP care**
Mark’s case highlights several achievements in TTP care. Firstly, prompt diagnosis using blood film analysis and the testing of LDH levels as useful tools allowing rapid initiation of treatment.
Secondly, the identification of the immune basis of TTP has resulted in the introduction of appropriate immunosuppressive treatment that reduces the time patients spend in hospital. For example, rituximab shortens the time to remission and in-
patient care to a median of 14 days or 21 days if admitted to ICU. Finally, the introduction of the novel anti-VWF antibody caplacizumab into the patient treatment pathway results in quicker normalisation of the platelet count and reduces the number of PEX procedures required and days in hospital. **[1]** Mark’s case exemplifies this.
## **What is the future for Mark?**
TTP is a chronic condition that requires lifelong follow up. There is a 30–50% risk of relapse, which can be averted by monitoring ADAMTS 13 activity levels in an out-patient setting. When the levels drop from normal (complete remission) to 15–20% (ADAMTS 13 relapse), despite normal routine laboratory parameters, further treatment with rituximab is given to normalise ADAMTS 13 activity levels and re-achieve complete remission.
The treatment pathway in acute TTP and the longterm monitoring of this condition have resulted in a significant decrease in mortality, preventing the likelihood of the condition worsening, failing to respond to treatment and relapse. The recent commissioning of regional TTP centres in England will enable equity of care and improve national outcomes in this rare but devastating condition.
_**1.** Scully M, Cataland SR, Peyvandi F et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 2019;380:335–346._
67
66
" This year the College has responded to external consultations from a wide range of organisations, agencies and societies, providing invaluable input to improve patient care and safety. Our Specialty Advisory Committees are integral to this process, providing us with evidence and advice." 05
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS** ANNUAL REPORT & ACCOUNTS
**SECTION 05** OUR GOVERNANCE
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS SECTION 05** ANNUAL REPORT & ACCOUNTS OUR GOVERNANCE
## Governance of the College
**Council and Trustee Board (as at 30 June 2022)**
- Dr Gareth McKeeman, Chair, Northern Ireland Regional Council
- Dr Bernard Croal, Chair, Scotland Regional Council
- Dr Jonathan Kell, Chair, Wales Regional Council
**Trustee Board**
- Mr Robert Smith, Chair and Lay Trustee
- Mr Robert Smith, Chair, Trustee Board
- Professor Michael Osborn, President
- Professor Ismail Matalka, Chair, International Committee
- Professor Sarah Coupland, Vice President for Communications
- **Nationally Elected Council Members**
- Professor Angharad Davies, Vice President for Learning
- Professor Simon Cross, Elected
- Professor Peter Johnston, Vice President for Professionalism • Professor Roger Feakins, Elected
- Dr Giovanni Satta, Elected
- Dr Andrew Boon, Treasurer
- Dr Ravinder Sodi, Elected
- Dr Lance Sandle, Registrar
- Dr Stephen Morley, Assistant Registrar
**Regionally Elected Council Members**
- Dr Gareth McKeeman, Chair, Northern Ireland Regional Council
- Dr Laszlo Igali, England, Midlands and East Region
- Dr Bernard Croal, Chair, Scotland Regional Council
- Dr Rachael Liebmann, England, London Region
- Dr Jonathan Kell, Chair, Wales Regional Council
- Wales Regional Council • Dr Negar Maghsoodi,
- • Dr Anita Hill, Co-opted Trustee England, South Region
- Dr Elijah Matovu, Co-opted Trustee • Dr Alison Robb, England, • Ms Jill Gauntlett, Lay Trustee North Region
- Mr Vincent Voon, Lay Trustee
- **Co-opted Council Members** • Dr Lisa Ayers, Chair, Healthcare Science Committee
## **Council Members**
- Professor Michael Osborn, President (Chair)
- • Professor Sarah Coupland, Vice President for Communications
- Dr John Ashcroft, Chair, Intercollegiate Committee on Haematology
- Professor Angharad Davies, Vice President for Learning
- Professor Neil Anderson, Chair, Clinical Biochemistry Specialty Advisory Committee (SAC)
- Professor Peter Johnston, Vice Advisory Committee (SAC) President for Professionalism • Dr Louise Jones, Chair, Genomics
- • Dr Andrew Boon, Treasurer and Reproductive Science SAC • Dr Lance Sandle, Registrar • Dr Darren Treanor, Chair, • Dr Stephen Morley, Digital Pathology Committee Assistant Registrar
- Dr Louise Jones, Chair, Genomics and Reproductive Science SAC
## **Observers to Council By Invitation**
- Dr Shruthi Narayan, Chair, Transfusion Medicine SAC
- Dr Shubha Allard, Clinical Director of Publishing and Engagement
- Ms Debra Padgett, IBMS Representative
- Dr Srinivas Annavarapu, Chair, Prenatal, Perinatal and Paediatric Pathology SAC
- Mr Nigel Pollard, Director of Corporate Services
- Dr David Bailey, Chair, Death Investigations Committee
- Dr Natasha Ratnaraja, Interim Chair, Joint Medical Microbiology and Medical Virology SAC
- Dr Adrian Bateman, Chair, Cellular Pathology SAC
- Professor David Roberts, Chair, Research Committee
- Ms Joanne Brinklow, Director of Learning
- Mr Daniel Ross, Chief Executive
- Dr Matthew Clarke, Chair, Trainees’ Advisory Committee
- Appointment process in place, Chair, Neuropathology SAC
- Professor Nicki Cohen, Clinical Director of Training & Assessment
- Ms Katherine Timms, Director of Professionalism
- Dr Nigel Cooper, Chair, Forensic Pathology SAC
- Dr David Turner, Chair, Histocompatibility and Immunogenetics SAC
- Dr Paul Craig, Chair, Dermatopathology Sub-Committee
- Vincent Voon, Lay Trustee
- Professor Paul Cross, Chair, Cytopathology Sub-Committee
- Cytopathology Sub-Committee • Dr Patrick Yong, Chair,
- • Ms Diane Gaston, Director Immunology SAC of Communications
- Ms Jill Gauntlett, Lay Trustee
- Dr Anita Hill, Co-opted Trustee
- Lt Col Dr Emma Hutley, Military Observer
- Professor Mary Keogan, Dean, Faculty of Pathology RCPI
- Professor Roberto La Ragione, Chair, Veterinary Pathology SAC
- • Dr Suzy Lishman, Chair, Medical Examiners Committee
- Dr Berenice Lopez, Clinical Director for Safety and Quality and Chair, Quality Assurance in Pathology Committee
- Dr Sanjiv Manek, Clinical Director of Examinations
- Professor Jo Martin, National Specialty Advisor for Pathology, NHS England/Improvement
- Dr Elijah Matovu, Co-opted Trustee
- Dr Stephen Morley, Chair, Toxicology SAC
70
71
**NOVEMBER** 2022
**ROYAL COLLEGE OF PATHOLOGISTS** ANNUAL REPORT & ACCOUNTS
**SECTION 05** OUR GOVERNANCE
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 05** OUR GOVERNANCE
## Financial report
The total income of the College amounted to £7.85 million, with expenditure of £7.35 million and a resultant surplus of £499k.
the first half of 2022 destroyed value almost everywhere. In sterling terms, the first period saw global equities rising 8.5%, whereas the second period witnessed a drop of 12.5%, for a net 12-month return of -5%. UK government bonds showed something surprisingly similar in direction, but much worse in outcome, with the first period up 0.6% and the second down -14% for a net 12-month return of -13.5%.
The investment portfolio decreased by £1.03 million, resulting in a deficit for the year of £536k. Membership subscriptions continue to be the largest source of income, amounting to £3.97 million. We measure our success by membership numbers, which stood at 12,500 at the beginning of the financial year and 13,000 at the end. Income from postgraduate education and examinations amounted to £2 million compared with £2.2 million last year. The prior year was unusual in terms of income as we were dealing with catch up as a result of COVID-19, effectively running an additional examination sitting. Examination operations have now normalised, with candidate numbers continuing to be strong. The College continued to hold many meetings virtually, thus saving on travel and accommodation costs.
As the investment mandate is to ensure that securities in the portfolio do not contravene the specific ethical requirements regarding direct investment in fossil fuels, mining, tobacco and armaments, this has affected the overall portfolio, resulting in a fall in value over the last 12 months. However, over the longer term, the investments have still delivered good positive returns.
Income from the trading activities of the College through the Events @ No 6 conference centre amounted to £901k, a considerable increase over the prior year. Following the relaxation of the restrictions that had to be imposed because of the COVID-19 pandemic, the centre has been able to operate throughout the year, with bookings returning slowly for the second half of 2021 and then more robustly for the first half of 2022. Due to a strong performance in the last three months of the financial year, the budget for the whole year has been exceeded, and bookings continue to hold up well going forward. The decision to retain the sales and marketing staff so that we could be on the front foot as the economy opened up was the right one, as we were able to respond quickly to booking enquiries and convert these into firm contracted business. The trading subsidiary currently has a net deficit and the trustees anticipate it will return to surplus within the next five years.
The accounts published overleaf are not the statutory accounts, but a summary of information relating to both the statement of financial activities and the balance sheet. The full financial statements have been audited and contain an unqualified audit report. They were approved by the Trustee Board on 4 August 2022 and have been submitted to the Charity Commission. Any member may request a copy of the full accounts by writing to the Chief Executive.
**Dr Andy Boon** Treasurer **Mr Daniel Ross** Chief Executive
On investment markets, the last 12 months were a tale of two contrasting halves. The second half of 2021 was still cheerful for markets, whereas
**Income 2021–2022**
**----- Start of picture text -----**
25%
Postgraduate
education &
51% examinations
Subscriptions
11%
6%
Trading activities
Digital education 1%
project
Total 1% International
100% 1% development
Professional
2%
Other standards
income 1% Conferences
& academic
Investment
activities
income
**----- End of picture text -----**
**----- Start of picture text -----**
Expenditure
2021–2022
19% 30%
Trading activities Postgraduate
& education education &
centre examinations
6%
5%
Conferences
Professional
standards 2% & academic
17% activities
Digital education
Communications
6% project 5%
Total Advisory committees 5% Workforce
100%
Clinical
5% effectiveness
International development
**----- End of picture text -----**
73
72
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 05** OUR GOVERNANCE
**NOVEMBER ROYAL COLLEGE OF PATHOLOGISTS** 2022 ANNUAL REPORT & ACCOUNTS
**SECTION 05** OUR GOVERNANCE
## **Consolidated Statement of Financial Activities for the year ended 30 June 2022**
**----- Start of picture text -----**
Unrestricted Unrestricted Restricted Total Funds Total Funds
General Designated Funds 30 June 30 June
Funds Funds 2022 2021
£ £ £ £ £
Income from:
Donations & legacies 588 - - 588 1,483
Charitable activities
Subscriptions 3,974,297 - - 3,974,297 3,785,867
Postgraduate education & examinations 1,981,094 - 13,500 1,994,594 2,199,501
Pathology Portal - - 500,000 500,000 175,000
International development 35,218 - 10,021 45,239 14,316
Conferences & academic activities 190,467 - - 190,467 262,107
Professional standards 57,844 - - 57,844 52,626
Research - - 40,000 40,000 -
Communications 115 - - 115 423
Trading activities 901,377 - - 901,377 68,324
Investments 77,614 - 1,863 79,477 93,946
Other 65,253 - - 65,253 79,820
Total income 7,283,867 - 565,384 7,849,251 6,733,413
Expenditure on:
Raising funds
Trading activities 1,350,735 1,154 50,297 1,402,186 946,270
Investment management fees 41,682 - - 41,682 23,557
Charitable activities
Postgraduate education - -
2,202,566 2,202,566 1,750,826
& examinations
Pathology Portal - - 160,987 160,987 138,871
-
International development 343,197 16,342 359,539 360,670
Conferences &
-
390,508 24,668 415,176 354,816
academic activities
Research - - - - 3,462
Professional standards 361,753 - - 361,753 269,543
Clinical effectiveness 365,192 7,768 - 372,960 259,300
Workforce 378,239 - - 378,239 313,000
Communications 1,217,789 - 821 1,218,610 1,096,090
Advisory committees 436,080 - - 436,080 413,749
Total expenditure 7,087,741 8,922 253,115 7,349,778 5,930,154
Included in the above expenditure is
£121,623 relating to non-recurrent
IT costs
Net income / (expenditure)
196,126 (8,922) 312,269 499,473 803,259
before net gains on investments
Net (losses) / gains on investments (874,964) - (160,984) (1,035,948) 1,035,62
Net income / (expenditure) (678,838) (8,922) 151,285 (536,475) 1,838,882
Transfers between funds (129,753) 128,753 1,000 - -
Net movement in funds (808,591) 119,831 152,285 (536,475) 1,838,882
Reconciliation of funds:
Total funds brought forward 7,596,098 29,436,817 1,458,634 38,491,549 36,652,667
Total funds carried forward 6,787,507 29,556,648 1,610,919 37,955,074 38,491,549
**----- End of picture text -----**
## **Consolidated Balance Sheet as at 30 June 2022**
**----- Start of picture text -----**
2022 2021
£ £
Fixed assets:
Tangible assets 37,777,416 38,403,585
Investments 5,233,165 6,294,113
Total fixed assets 43,010,581 44,697,698
Current assets:
Stocks 4,489 4,900
Debtors 803,693 477,465
Cash at bank and in hand 7,066,834 6,143,921
Total current assets 7,875,016 6,626,286
Liabilities:
Creditors: Amounts falling due within one year (4,607,566) (4,040,079)
Net current assets 3,267,450 2,586,207
Total assets less current liabilities 46,278,031 47,283,905
Creditors: Amounts falling due after more
(8,322,957) (8,792,356)
than one year
Total net assets 37,955,074 38,491,549
The funds of the College:
Unrestricted funds – general funds 6,787,507 7,596,098
Unrestricted funds – designated funds 29,556,648 29,436,817
Restricted funds 1,610,919 1,458,634
Total College funds 37,955,074 38,491,549
**----- End of picture text -----**
The financial statements were approved by the Trustee Board on 4 August 2022 and signed on behalf of the Trustee Board by Professor Mike Osborn, President, and Dr Andy Boon, Treasurer.
## **Independent Auditor’s Statement to the Trustees of the Royal College of Pathologists.**
The full financial statements were audited by Begbies, Chartered Accountants, and approved by the Trustee Board on 4 August 2022 and signed on their behalf by Professor Mike Osborn and Dr Andy Boon.
## **Begbies**
Chartered Accountants and Registered Auditors 9 Bonhill Street, London EC2A 4DJ
75
74
6 Alie Street, London E1 8QT 020 7451 6700 | www.rcpath.org
## @rcpath /rcpath © 2022 The Royal College of Pathologists Registered Charity in England and Wales | Number 261035
**----- Start of picture text -----**
pathology
**----- End of picture text -----**
**----- Start of picture text -----**
diamond jubilee
**----- End of picture text -----**